0001437749-16-031581.txt : 20160512 0001437749-16-031581.hdr.sgml : 20160512 20160511210210 ACCESSION NUMBER: 0001437749-16-031581 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160512 DATE AS OF CHANGE: 20160511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Interpace Diagnostics Group, Inc. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 222919486 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 161641440 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, BUILDING A STREET 2: 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 8622077800 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, BUILDING A STREET 2: 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 10-Q 1 pdii20160331_10q.htm FORM 10-Q pdii20160331_10q.htm Table Of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549


FORM 10-Q


 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the quarterly period ended March 31, 2016

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the transition period from _______________ to _______________

 

 

Commission File Number: 000-24249

 

Interpace Diagnostics Group, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

22-2919486

(State or other jurisdiction of Incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

Morris Corporate Center 1, Building A

300 Interpace Parkway, Parsippany, NJ 07054

(Address of principal executive offices and zip code)

 

(844) 405-9655

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.   See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large accelerated filer   ☐

Accelerated filer   ☐

Non-accelerated filer  ☐

Smaller reporting company  ☒

   

(Do not check if a  smaller

reporting company)

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐    No ☒

 

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

 

 

Class

 

Shares Outstanding

May 6, 2016

Common stock, $0.01 par value

    18,162,671    

 

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

FORM 10-Q FOR PERIOD ENDED MARCH 31, 2016

TABLE OF CONTENTS

 

   

Page No.

 

PART I - FINANCIAL INFORMATION

   
       

Item 1.

Unaudited Interim Condensed Consolidated Financial Statements

   
       
 

Condensed Consolidated Balance Sheets at March 31, 2016 and December 31, 2015 (unaudited)

3  
       
 

Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2016 and 2015 (unaudited)

4  
       
 

Condensed Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2016 and 2015 (unaudited)

  5  
       
 

Notes to Unaudited Interim Condensed Consolidated Financial Statements

 6  
       

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

  19  
       

Item 4.

Controls and Procedures

  26  
       
       
 

PART II - OTHER INFORMATION

   
       

Item 1.

Legal Proceedings

  27  
       

Item 6.

Exhibits

  27  
       

Signatures

 28  

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except share and per share data)

 

   

March 31,

   

December 31,

 
   

2016

   

2015

 
                 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 4,340     $ 8,310  

Short-term investments

    -       106  

Accounts receivable, net

    2,780       2,806  

Other current assets

    3,024       2,569  

Current assets from discontinued operations

    1,530       5,374  

Total current assets

    11,674       19,165  

Property and equipment, net

    1,330       1,460  

Other intangible assets, net

    42,522       43,492  

Other long-term assets

    1,066       3,255  

Non-current assets from discontinued operations

    183       340  

Total assets

  $ 56,775     $ 67,712  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               

Current liabilities:

               

Accounts payable

  $ 1,245     $ 1,560  

Accrued salary and bonus

    2,869       2,424  

Other accrued expenses

    6,655       5,961  

Current portion of long-term debt, net of debt discount

    2,463       1,164  

Current liabilities from discontinued operations

    6,514       12,264  

Total current liabilities

    19,746       23,373  

Contingent consideration

    17,890       17,890  

Long-term debt, net of debt discount

    6,137       7,233  

Other long-term liabilities

    4,696       6,178  

Total liabilities

    48,469       54,674  
                 

Commitments and contingencies (Note 6)

               
                 

Stockholders’ equity:

               

Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding

    -       -  

Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively

    187       187  

Additional paid-in capital

    125,800       132,522  

Accumulated deficit

    (116,038 )     (111,252 )

Accumulated other comprehensive income

    -       13  

Treasury stock, at cost (542,543 and 1,042,543 shares, respectively)

    (1,643 )     (8,432 )

Total stockholders' equity

    8,306       13,038  

Total liabilities and stockholders' equity

  $ 56,775     $ 67,712  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited, in thousands, except for per share data)

 

   

Three Months Ended

 
   

March 31,

 
   

2016

   

2015

 
                 
                 

Revenue, net

  $ 3,035     $ 2,117  

Cost of revenue (excluding amortization of $970 and $870, repectively)

    1,179       1,574  

Gross profit

    1,856       543  

Operating expenses:

               

Sales and marketing

    1,547       2,226  

Research and development

    323       232  

General and administrative

    2,816       3,339  

Acquisition related amortization expense

    970       870  

Total operating expenses

    5,656       6,667  
                 

Operating loss

    (3,800 )     (6,124 )
                 

Interest expense

    (203 )     (848 )

Other income (expense), net

    6       (86 )

Loss from continuing operations before tax

    (3,997 )     (7,058 )

Provision (benefit) for income tax

    9       (73 )

Loss from continuing operations

    (4,006 )     (6,985 )

(Loss) income from discontinued operations, net of tax

    (780 )     3,117  

Net loss

  $ (4,786 )   $ (3,868 )
                 

Other comprehensive income:

               

Unrealized holding gain on available-for-sale securities, net

    -       -  

Comprehensive loss

  $ (4,786 )   $ (3,868 )
                 

Basic and diluted loss per share of common stock:

               

From continuing operations

  $ (0.23 )   $ (0.46 )

From discontinued operations

    (0.04 )     0.21  

Net loss per basic and diluted share of common stock

  $ (0.27 )   $ (0.26 )

Weighted average number of common shares and common share equivalents outstanding:

               

Basic

    17,762       15,037  

Diluted

    17,762       15,037  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

 

   

Three Months Ended

 
   

March 31,

 
   

2016

   

2015

 
                 
                 

Cash Flows From Operating Activities

               

Net loss

  $ (4,786 )   $ (3,868 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    1,257       1,195  

Realignment accrual accretion

    16       35  

Interest accretion

    203       261  

Provision for bad debt

    89       96  

Gain on sale of discontinued operations

    -       (285 )

Stock-based compensation

    67       396  

Other (gains), losses and expenses, net

    (13 )     -  

Other changes in assets and liabilities:

               

Decrease (increase) in accounts receivable

    4,270       (5,229 )

Decrease in unbilled receivable

    16       420  

Increase in other current assets

    (460 )     (438 )

Decrease in other long-term assets

    689       2,156  

Decrease in accounts payable

    (1,887 )     (1,274 )

(Decrease) increase in unearned contract revenue

    (11 )     4,144  

(Decrease) increase in accrued salaries and bonus

    (372 )     1,040  

Decrease in accrued liabilities

    (2,566 )     (4,602 )

(Decrease) increase in long-term liabilities

    (482 )     336  

Net cash used in operating activities

    (3,970 )     (5,617 )
                 

Cash Flows From Investing Activities

               

Purchase of property and equipment

    -       (464 )

Net cash used in investing activities

    -       (464 )
                 

Cash Flows From Financing Activities

               

Cash paid for repurchase of restricted shares

    -       (26 )

Net cash used in financing activities

    -       (26 )
                 

Net decrease in cash and cash equivalents

    (3,970 )     (6,107 )

Cash and cash equivalents – beginning

    8,310       23,111  

Cash and cash equivalents – ending

  $ 4,340     $ 17,004  

Cash paid for interest

  $ -     $ 818  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Tabular information in thousands, except per share amounts)

 

 

1.

BASIS OF PRESENTATION

 

The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc. (the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC, and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016.  The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.  All significant intercompany balances and transactions have been eliminated in consolidation.  Discontinued operations include the Company's wholly-owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services business unit. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the three-month period ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

 

2.

LIQUIDITY AND MANAGEMENT'S PLANS

 

For the three months ended March 31, 2016, the Company incurred a net loss of $4.8 million and cash used in operating activities was $4.0 million.  The Company did not raise any capital or incur any additional debt during the first quarter of 2016. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to ramping up its commercial operations, further developing its products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations. The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2016, the Company had cash and cash equivalents of $4.3 million, net accounts receivable of $2.8 million and current liabilities of $19.7 million.

 

As a result of the sale of substantially all of its Commercial Services Organization (CSO) business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on the molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company will require additional capital in 2016 and beyond and in order to obtain such capital and fund its operations, may be required to restructure all or a portion of its obligations related to the sale of its CSO business. There is, however, no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that is sufficient to fund the Company's operations in 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development and other sources. Additionally, the Company intends to help meet its capital needs by driving revenue growth of our commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

 

A summary of the Company’s significant contractual obligations as of March 31, 2016 over the next 12 months are as follows:

 

   

Total

   

0 to 3

months

   

3 to 6

months

   

6 to 12

months

 

Note due Redpath Equityholders

  $ 2,668     $ -     $ -     $ 2,668  

Severance obligations

    3,675       2,774       901       -  

Department of Justice ("DOJ") settlement

    750       -       85       665 *

Asuragen Deferred Purchase Price

    500       300       200       -  

Total obligations

  $ 7,593     $ 3,074     $ 1,186     $ 3,333  

 

* Estimated liability based on our current revenue expectation. 

 

3.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.

 

Reclassifications

 

The Commercial Services business in the period ended March 31, 2015 has been reclassified to discontinued operations to conform to the current period presentation.

 

Receivables and Allowance for Doubtful Accounts

 

The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)

 

The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $0.9 million allowance for doubtful accounts as of March 31, 2016.

 

 

Other Current Assets

 

Other current assets consisted of the following as of March 31, 2016 and December 31, 2015:

 

   

March 31, 2016

   

December 31, 2015

 

Indemnification assets

  $ 1,375     $ 875  

Letters of credit

    344       360  

Other receivables

    960       1,048  

Prepaid expenses

    243       180  

Other

    102       106  
    $ 3,024     $ 2,569  

 

 

Other Intangible Assets

 

The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.

 

Discontinued Operations

 

The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations for further information.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

Basic and Diluted Net Loss per Share

 

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2016 and 2015 is as follows:

 

   

Three Months Ended

 
   

March 31,

 
   

2016

   

2015

 

Basic weighted average number of common shares

    17,762       15,037  

Potential dilutive effect of stock-based awards

    -       -  

Diluted weighted average number of common shares

    17,762       15,037  

 

The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:

 

 

   

March 31,

 
   

2016

   

2015

 

Options

    -       25  

Stock-settled stock appreciation rights (SARs)

    1,027       1,066  

Restricted stock and restricted stock units (RSUs)

    1,317       1,632  

Performance contingent SARs

    -       188  
      2,344       2,911  

 

 

4.

OTHER INTANGIBLE ASSETS

 

 

The net carrying value of the identifiable intangible assets as of March 31, 2016 is as follows: 

 

           

As of March 31, 2016

 
   

Life

   

Carrying

 
   

(Years)

   

Amount

 

Diagnostic assets:

               

Asuragen acquisition:

               

Thyroid

    9     $ 8,519  

Pancreas

    7       2,882  

Biobank

    4       1,575  

RedPath acquisition:

               

Pancreas test

    7       16,141  

Barrett's test

    9       18,351  

Total

          $ 47,468  

Diagnostic lab:

               

CLIA Lab

    2.3     $ 609  
                 

Accumulated Amortization

          $ (5,555 )
                 

Net Carrying Value

          $ 42,522  

  

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

 

Amortization expense was $1.0 million and $0.9 million for the three month periods ended March 31, 2016 and 2015, respectively. Amortization of the Company's diagnostic assets begin upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2016

   

2017

   

2018

   

2019

   

2020

 
$ 4,889     $ 6,097     $ 5,949     $ 5,703     $ 5,703  

 

 

5.

FAIR VALUE MEASUREMENTS

 

The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

 

 

Level 1:

Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.

 

 

Level 2:

Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.

 

 

Level 3:

Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 

   

As of March 31, 2016

   

Fair Value Measurements

 
   

Carrying

   

Fair

   

As of March 31, 2016

 
   

Amount

   

Value

   

Level 1

   

Level 2

     

Level 3

 

Assets:

                                         

Cash and cash equivalents:

                                         

Cash

  $ 3,564     $ 3,564     $ 3,564     $ -  

 

  $ -  

Money market funds

    776       776       776       -         -  
    $ 4,340     $ 4,340     $ 4,340     $ -       $ -  

Marketable securities:

                                         

U.S. Treasury securities

  $ 553     $ 553     $ 553     $ -       $ -  

Liabilities:

                                         

Contingent consideration:

                                         

Asuragen

  $ 4,628     $ 4,628     $ -     $ -       $ 4,628  

RedPath

    13,921       13,921       -       -         13,921  
    $ 18,549     $ 18,549     $ -     $ -       $ 18,549  

 

 

The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of March 31, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3).

 

In connection with the acquisition of assets from Asuragen and the acquisition of RedPath, the Company has recorded $4.6 million and $13.9 million of contingent cash consideration related to deferred payments and revenue based payments, respectively. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.  There was no change in the fair value of the contingent consideration during the period ended March 31, 2016.

 

The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.  There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.

 

Certain of the Company's non-financial assets, such as other intangible assets, are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

 

 

6.

COMMITMENTS AND CONTINGENCIES

 

Letters of Credit

 

As of March 31, 2016, the Company had $0.5 million in letters of credit outstanding as required by its existing insurance policies and its facility leases. These letters of credit are collateralized by certain investments.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

Contingency 

 

In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace Diagnostics, LLC (Interpace LLC) entered into a Contingent Consideration Agreement with RedPath Equityholder Representative, LLC (the Equityholder Representative). Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company’s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG® for the management of Barrett’s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen™ for predicting risk of progression from Barrett’s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its Commercial Services (CSO) business in December 2015, decreasing the balance in Treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million.

 

Litigation

 

Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

 

The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of March 31, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.

 

In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (“DOJ”). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million.

  

Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for up to $2.5 million of the obligation, with the first $0.5 million payable by the Company. At March 31, 2016, the Company has recorded an indemnification asset of $1.5 million of which $0.5 is included in other current assets and $1.0 million is included in other non-current assets. At March 31, 2016, the Company has $1.8 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.8 million is included in other accrued expenses and $1.0 million is included in other long-term liabilities. In May 2016, the Company negotiated a payment plan with the DOJ to pay the $250,000 currently due based on its 2015 revenues in three relatively equal installments in August 2016, October 2016 and February 2017.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

Prolias Technologies, Inc. v. PDI, Inc.

 

On April 8, 2015, Prolias Technologies, Inc., or Prolias, filed a complaint (the Complaint) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled Prolias Technologies, Inc. v. PDI, Inc. (Docket No. MRS-L-899-15).  In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto, collectively the Agreement, whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as "Thymira."  Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer.

 

Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit.

 

On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied liability for the claims being asserted in the Complaint. In the Counterclaim, the Company asserted claims against Prolias for breaches of the Agreement and for a declaratory judgment. The Company seeks damages from Prolias in excess of $500,000 plus interest and attorney’s fees and costs, together with a declaration compelling Prolias to execute and deliver to the Company a promissory note in the amount of One Million Five Hundred Thousand Dollars ($1,500,000.00) to evidence Prolias’ obligation to repay the Company for amounts that were advanced.

 

After the Answer and Counterclaim were filed, the Company and Prolias exchanged paper discovery.  In early December 2015, Prolias replaced its counsel with new counsel.  Thereafter, on December 18, 2015, Prolias filed an Order to Show Cause and Temporary Restraining Order (TRO) that sought to (a) enjoin the Company from selling the assets that comprise its CSO business to Publicist Healthcare Communications Group and (b) disqualify the Company's counsel from representing it in the litigation.

 

On December 21, 2015, the Court held a hearing on Prolias's application to temporarily enjoin the sale of the CSO business. Following the hearing the Court denied Prolias's application for a TRO and set a hearing date on the motions to disqualify counsel and to obtain an injunction.

 

On February 4, 2016, the Court heard argument on Prolias's motions to disqualify the Company’s counsel and to obtain an injunction with respect to the CSO sale. Following the hearing, the Court entered orders denying the motion to disqualify and denying the motion for an injunction.

 

On February 24, 2016, Prolias filed a motion before the New Jersey Appellate Division to appeal on an interlocutory basis the order denying the motion to disqualify.  The Company filed its opposition to the motion on March 7, 2016.  It is not known when the Appellate Division will rule on the motion for leave to take an interlocutory appeal, and further it is not known whether, if Prolias is successful in obtaining leave to appeal, what would be the result of the appeal. Progress on the case has been stayed pending resolution of this issue. In the interim, counsel for Prolias has filed for permission to withdraw as counsel, citing nonpayment of its bills. That motion also remains pending.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

 

The Company denies that it is liable to Prolias for any of the claims asserted in the Complaint and it intends to (a) vigorously defend itself against those claims, (b) pursue all claims asserted in the Counterclaim and (c) vigorously oppose the motion for leave to appeal.

 

Severance 

 

In 2015, in connection with the sale of substantially all of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to $3.7 million.

 

During the three month period ended March 31, 2016 the Company recorded additional severance obligations as it discontinued the remainder of its CSO business and recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations within general and administrative expenses in the Condensed Consolidated Statement of Comprehensive Loss. A rollforward of the severance activity is as follows:

 

   

Continuing

   

Discontinued

         
   

Operations

   

Operations

   

Total

 
                         

Balance as of December 31, 2015

  $ 2,011     $ 1,074     $ 3,085  

Accruals

    459       659       1,118  

Payments

    (140 )     (388 )     (528 )

Balance as of March 31, 2016

  $ 2,330     $ 1,345     $ 3,675  

 

7.

ACCRUED EXPENSES AND LONG-TERM LIABILITIES

 

Other accrued expenses consisted of the following as of March 31, 2016 and December 31, 2015:

 

   

March 31, 2016

   

December 31, 2015

 

Facilities realignment accrual

  $ -     $ 43  

Self insurance accruals

    66       137  

Indemnification liability

    875       875  

Contingent consideration

    659       659  

Rent payable

    104       127  

DOJ settlement

    750       250  

Accrued professional fees

    1,084       775  

Taxes payable

    622       591  

Unclaimed property

    544       546  

All others

    1,951       1,958  
    $ 6,655     $ 5,961  

 

 

 

Long-term liabilities consisted of the following as of March 31, 2016 and December 31, 2015:

 

 

   

March 31, 2016

   

December 31, 2015

 

Rent payable

  $ 27     $ 52  

Uncertain tax positions

    3,468       3,425  

DOJ settlement (indemnified by RedPath)

    1,000       2,500  

Other

    201       201  
    $ 4,696     $ 6,178  

 

 

8.

STOCK-BASED COMPENSATION

 

Stock Incentive Plan

 

In 2015, the Board and stockholders approved the Company’s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company’s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan.  The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan.  Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee.  Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for issuance under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder. 

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

 

SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant.  The restricted shares and restricted stock units (RSU’s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

 

In February 2016, certain employees and members of the Company’s Board of Directors were granted approximately 1.3 million RSU’s at a weighted average grant price of $0.25. These shares vest one-third each year on the anniversary of the date of grant.

 

The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the three month periods ended March 31, 2016 and March 31, 2015: 

 

   

Three Months Ending

 
   

March 31,

 
   

2016

   

2015

 

Risk-free interest rate

    -       0.97%  

Expected life (years)

    -       3.5  

Expected volatility

    -       52.03%  

Dividend yield

    -       -  

 

The Company recognized approximately $0.1 million and $0.2 million of stock-based compensation expense during each of the three month periods ended March 31, 2016 and 2015, respectively.

 

9.

INCOME TAXES

 

Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.  As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.  The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- month periods ended March 31, 2016 and 2015: 

 

 

 

   

Three Months Ended

 
   

March 31,

 
   

2016

   

2015

 

Provision (benefit) for income tax

  $ 9     $ (73 )

Effective income tax rate

    0.2 %     1.0 %

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

Income tax expense for the quarter ended March 31, 2016 was due to minimum state and local taxes. Income tax benefit for the quarter ended March 31, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.

 

10.

SEGMENT INFORMATION

 

Effective December 31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its Commercial Services business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

 

The Company's molecular diagnostics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.

 

11.

DISCONTINUED OPERATIONS

 

The table below presents the significant components of Commercial Services, Group DCA's, Pharmakon's and TVG’s results included in Loss from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the years ended March 31, 2016 and 2015.

 

 

   

Three Months Ending March 31,

 
   

2016

   

2015

 

Revenue, net

  $ 1,644     $ 36,463  
                 

(Loss) income from discontinued operations, before tax

    (735 )*     3,118  

Income tax expense

    45       1  

(Loss) income from discontinued operations, net of tax

  $ (780 )   $ 3,117  

 

* Approximately $659,000 of the balance relates to severance relating to terminated employees.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts)  

 

 

The assets and liabilities classified as discontinued operations relate to Commercial Services, Group DCA, Pharmakon, and TVG. As of March 31, 2016 and December 31, 2015, these assets and liabilities are in the accompanying balance sheets as follows:

 

   

For the Three Months Ended

March 31, 2016

   

For the Year Ended

December 31, 2015

 
   

CSO

   

DCA/

TVG

   

Total

   

CSO

   

DCA/

TVG

   

Total

 

Accounts receivable, net

  735     -     735     3,296     -     3,296  

Unbilled receivable, net

    -       -       -       16       -       16  

Other

    795       -       795       2,062       -       2,062  

Current assets from discontinued operations

    1,530       -       1,530       5,374       -       5,374  

Property and equipment, net

    33       -       33       190       -       190  

Other

    -       150       150       -       150       150  

Long-term assets from discontinued operations

    33       150       183       190       150       340  

Total assets

  1,563     150     1,713     5,564     150     5,714  
                                                 

Accounts payable

  2,195     -     2,195     3,767     -     3,767  

Unearned contract revenue

    -       -       -       11       -       11  

Accrued salary and bonus

    2,219       -       2,219       3,036       -       3,036  

Other

    1,812       288       2,100       5,092       358       5,450  

Current liabilities from discontinued operations

    6,226       288       6,514       11,906       358       12,264  

Total liabilities

  6,226     $ 288     6,514     11,906     358     12,264  

 

12.

LONG-TERM DEBT

 

On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the Equityholder Representative, dated October 31, 2014 (as amended, the Note).

 

The Note is for $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October 1, 2016. In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In October 2015, in connection with the sale of substantially all of the CSO business in December 2015, the Note was amended to, among other things:

 

 

permit the Company to enter into a revolving loan facility,

 

permit the Company to sell the CSO business and to use the proceeds of the CSO sale to pay off the amounts due under the existing $20 million Credit Agreement and to continue to make payments on the debt due under the Note in accordance with the terms of the Note,

 

provide that, upon written request by the Equityholder Representative on April 30, 2016, the Company would make a one-time principal payment in the amount of $1,333,750 on July 1, 2016 rather than as originally due on July 1, 2018 (which such request the Company did not receive), and

 

provide that the 500,000 shares of the Company’s common stock to be issued upon the commercial launch of PancraGen® for the management of Barrett’s esophagus would be deemed earned by the former RedPath Equityholders as of the closing of the sale of the CSO business (see Note 6, Commitments and Contingencies).

 

 

The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries in favor of the Equityholder Representative. Pursuant to the guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended March 31, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. As of March 31, 2016, the balance of the Note is approximately $8.6 million and the unamortized discount is $2.1 million.

 

Principal payments due related to the long-term debt over next three years are as follows: 

 

   

2016

 

2017

 

2018

Note

  $ 1,334       $ 5,335       $ 4,001    

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Tabular information in thousands, except per share amounts) 

 

 

As discussed in Footnote 6, the Company currently has an indemnification asset and liability of $1.5 million ($0.5 million short-term and $1.0 million long-term) relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. As the Company makes payments to the DOJ, it may reduce the balance owed on the note by the same amount.

  

In addition, the Company entered into the Credit Agreement with the Agent and the Lenders, as defined in the agreement, in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the loan was October 31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement.

 

Upon the sale of substantially all of the Commercial Services (CSO) business on December 22, 2015, the Company was obligated to use a portion of the net proceeds from the transaction to pay the balance of the outstanding Loan in the aggregate principal amount of $20.0 million, an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015.

  

13.

SUPPLEMENTAL CASH FLOW INFORMATION

 

The following table represents cash flows (used in) provided by the Company's discontinued operations for the three months ended March 31, 2016 and 2015:

 

   

For The Three Months Ended March 31

 
   

2016

   

2015

 

Net cash (used in) provided by operating activities of discontinued operations

  $ (2,171 )   $ 6,073  
                 

Net cash provided by (used in) investing activities of discontinued operations

  $ -     $ -  

 

 

14.

RECENT ACCOUNTING PRONOUNCEMENTS

 

 

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance permits the use of either a retrospective or cumulative effect transition method. In July 2015, the FASB approved a one-year deferral of the effective date of the guidance to interim and annual periods beginning on or after December 15, 2017. Early adoption is permitted but not before the original effective date of December 15, 2016. The Company has not yet selected a transition method and is currently evaluating the impact of the amended guidance on the Company’s consolidated financial position, results of operations and related disclosures.

 

In August 2014, the FASB issued guidance on determining when and how to disclose going-concern uncertainties in financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its consolidated financial position, results of operations and related disclosures.

 

In March 2016, the FASB issued guidance which clarifies the implementation guidance on principal versus agent considerations in the revenue recognition standard issued in May 2014. The new standard clarifies how an entity should identify the unit of accounting (i.e. the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The effective date and transition requirements are the same as the effective date and transition requirements in the May 2014 revenue standard (Accounting Standards Codification 606). The Company is currently assessing the adoption methodology and the impact the adoption of these ASUs will have on its consolidated financial position, results of operations and related disclosures.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

FORWARD-LOOKING STATEMENTS

 

 This quarterly report on Form 10-Q (Form 10-Q) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934. as amended (the Exchange Act).  Statements that are not historical facts, including statements about our plans, objectives, beliefs and expectations, are forward-looking statements.  Forward-looking statements include statements preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “plans,” “estimates,” “intends,” “projects,” “should,” "could," “may,” “will” or similar words and expressions.  These forward-looking statements are contained throughout this Form 10-Q.

 

Forward-looking statements are only predictions and are not guarantees of future performance.  These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control.  These predictions are also affected by known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied by any forward-looking statement.  Many of these factors are beyond our ability to control or predict.  Such factors include, but are not limited to, the following:

 

 

our ability to profitably grow our business, including our ability to finance our business on acceptable terms and successfully compete in the market;

 

our ability to obtain broad adoption of and reimbursement for our molecular diagnostic tests in a changing reimbursement environment;

 

whether we are able to successfully utilize our operating experience to sell our molecular diagnostic tests;

 

our limited operating history as a molecular diagnostics company;

 

our dependence on a concentrated selection of payors for our molecular diagnostic tests;

 

the demand for our molecular diagnostic tests from physicians and patients;

 

our reliance on our internal sales forces for business expansion;

 

our dependence on third parties for the supply of some of the materials used in our molecular diagnostic tests;

 

our ability to scale our operations, testing capacity and processing technology;

 

our ability to restructure, defer or convert into equity certain of our debt obligations and liabilities;

 

product liability claims against us;

 

our involvement in current and future litigation against us;

 

the effect current and future laws, licensing requirements and regulation have on our business especially the changing FDA environment as it relates to molecular diagnostics;

 

our exposure to environmental liabilities as a result of our business;

 

the susceptibility of our information systems to security breaches, loss of data and other disruptions;

 

our billing practices and our ability to collect on claims for the sale of our molecular diagnostic tests;

 

our ability to attract and retain qualified sales representatives and other key employees and management personnel;

 

competition in the segment of the molecular diagnostics industry in which we operate or expects to operate;

 

our ability to obtain additional funds in order to implement our business models and strategies;

 

the results of any future impairment testing for other intangible assets;

 

our ability to successfully identify, complete and integrate any future acquisitions and the effects of any such items on our revenues, profitability and ongoing business;

 

our compliance with our license agreements and our ability to protect and defend our intellectual property rights;

 

our ability to to remain listed on NASDAQ despite our having received a notice of delisting;

 

the effect our largest stockholder may have on us;

 

our ability to meet the legacy obligations of our CSO business, previously sold;

 

failure of third-party service providers to perform their obligations to us; and

 

the volatility of our stock price and fluctuations in our quarterly and annual revenues and earnings.

 

 

INTERPACE DIAGNOSTICS GROUP, INC. 

 

Please see Part I – Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, as well as other documents we file with the U.S. Securities and Exchange Commission (SEC) from time-to-time, for other important factors that could cause our actual results to differ materially from our current expectations as expressed in the forward-looking statements discussed in this Form 10-Q.  Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. In addition, these statements speak only as of the date of the report in which they are set forth and, except as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

OVERVIEW

 

We are focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. We currently have three commercialized molecular tests: PancraGen®, a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing our proprietary PathFinder platform; ThyGenX®, which assesses thyroid nodules for risk of malignancy; and ThyraMIR®, which assesses thyroid nodules risk of malignancy utilizing a proprietary gene expression assay. We also have on the market in a limited manner, an assay utilizing our PathFinder platform for Barrett's Esophagus, an esophageal cancer risk classifier. Additonally, we have in development an assay for biliary cancer.

 

Our mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. We aim to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers. Our customers consist primarily of physicians, hospitals and clinics.

 

With the completion of the CSO transaction and wind down of related activities through March 2016, we are now concentrating our efforts principally on our molecular diagnostics business by offering solutions for determining the presence of certain cancers to clinicians and their patients as well as providing prognostic pre-cancerous information, which we believe to be an expanding market opportunity. We believe that the molecular diagnostics market offers significant growth and strong patient value given the substantial opportunity it affords to lower healthcare costs by helping to reduce unnecessary surgeries and avoiding too frequent monitoring. We are keenly focused on growing our test volumes, securing reimbursement, and driving revenue for our three commercialized innovative tests as well as expanding our business by developing and promoting synergistic products in our market.

 

In March 2016, we announced that we implemented a broad-based program to maximize efficiencies and cut costs as we focus on improving cash flows and profitability while completing our transition to a standalone molecular diagnostics business. In addition to reducing headcount, we have realigned our compensation structure, consolidated positions, eliminated programs and development plans that did not have near term benefits, and streamlined and right-sized operating systems while reducing overhead.

 

We have been successfully expanding the reimbursement of our products in 2016:  

 

 

In April 2016, we announced reimbursement approval by a major national managed care organization to cover ThyraMIR®, the first micro RNA classifier made available for improving the diagnosis of indeterminate thyroid nodules. This approval brings the total number of covered lives in the United States for ThyraMIR to more than 130 million. Coverage by this national plan was previously approved for ThyGenX®, our Next Gen oncogene panel used to assist physicians in distinguishing between benign and malignant thyroid nodules. 

 

In April 2016, we also announced that we received coverage for all of our products by Galaxy Health Network, a national managed care provider with over 3.5 million covered lives. Galaxy Health Network's Preferred Provider Organization includes a network of over 400,000 contracted physicians, 2,700 hospitals and 47,000 ancillary providers.

     

 

INTERPACE DIAGNOSTICS GROUP, INC. 

 

 

In April 2016, we announced new coding by Novitas Solutions for PancraGen®. Novitas Solutions, has assigned a new molecular CPT code (Current Procedural Terminology) to its PancraGen® test for pancreatic cysts.  Prior to this coding change the test was covered under a miscellaneous chemistry code, which is used for billing a wide range of tests across the laboratory industry and does not effectively differentiate between technologies that have significantly different features and offer unique benefits to patients with specific diseases. 

 

In February 2016, we announced that we received Medicare approval for coverage of ThyraMIR. As a result, the ThyraMIR test is now accessible to more than 50 million Medicare covered patients nationwide effective December 14, 2015. ThyGenX® is already covered by Medicare, therefore, the addition of coverage for ThyraMIR provides Medicare covered patients the benefits of the ThyGenX/ThyraMIR combination test.

 

In January 2016, we announced that our Medicare administrative carrier, Novitas Solutions, issued a new local coverage determination (LCD) for PancraGen®. The LCD provides the specific circumstances under which PancraGen® is covered. The new policy is non-conditional and may improve the efficiency of the testing process for doctors and patients. The LCD covers approximately 55 million patients, bringing the total patients covered for PancraGen® to nearly 68 million.

 

On January 7, 2016, we were notified by NASDAQ that we were no longer in compliance with the minimum bid price requirements of the stock exchange and that we have until July 5, 2016 to regain compliance with this requirement or face delisting. We are currently considering available options to regain compliance.

 

 

DESCRIPTION OF REPORTING SEGMENTS

 

We currently operate under one operating segment, which is our molecular diagnostic business. Until December 22, 2015 prior to the CSO sale, we operated under two reporting segments: Commercial Services and Interpace Diagnostics. The Commercial Services business in the period ended March 31, 2016 is reported as discontinued operations and has been reclassified to discontinued operations in the period ended March 31, 2015 to conform to the current period presentation.

 

Interpace Diagnostics

 

 

Interpace Diagnostics revenue is generated from the use of our proprietary tests. Our performance obligation is fulfilled upon the completion, review and release of test results. In conjunction with fulfilling these services, we bill the third-party payor or hospital. We recognize revenue related to billings for Medicare, Medicare Advantage, hospitals, and other third party payers on an accrual basis, net of contractual adjustment, when a contract is in place, a reliable pattern of collectability exists and collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare, Medicare Advantage, insurance companies, and the contractual rate or the amounts agreed to with hospitals.

 

 

Until a contract has been negotiated with a commercial insurance carrier or governmental program, the services may or may not be covered by these entities' existing reimbursement policies. In addition, we do not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that insurance declines to reimburse us. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment, the related revenue is only recognized upon the earlier of payment notification or cash receipt. Accordingly, we recognize revenue from commercial insurance carriers and governmental programs without contracts, when payment is received.

 

Persuasive evidence of an arrangement exists and delivery is deemed to have occurred upon completion, review, and release of the test results and we will bill the third-party payor or hospital at such time. The assessment of the fixed or determinable nature of the fees charged for diagnostic testing performed, and the collectability of those fees, requires significant judgment by our management. Our management believes that these two criteria have been met when there is contracted reimbursement coverage or a predictable pattern of collectability with individual third-party payors or hospitals and accordingly, recognizes revenue upon delivery of the test results. In the absence of contracted reimbursement coverage or a predictable pattern of collectability, we believe that the fee is fixed or determinable and collectability is reasonably assured only upon request of third-party payor notification of payment or when cash is received, and we recognize revenue at that time.

 

 

INTERPACE DIAGNOSTICS GROUP, INC. 

 

Cost of services consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, and facility expenses.

 

CONSOLIDATED CONDENSED RESULTS OF OPERATIONS

 

The following table sets forth, for the periods indicated, certain statements of operations data. The trends illustrated in this table may not be indicative of future results.

 

Consolidated Condensed Results of Continuing Operations for the Quarter Ended March 31, 2016 Compared to the Quarter Ended March 31, 2015 (in thousands)

 

 

 

   

Three Months Ended

 
   

March 31,

 
   

2016

   

2016

   

2015

   

2015

 
                                 
                                 

Revenue, net

  $ 3,035       100.0 %   $ 2,117       100.0 %

Cost of revenue

    1,179       38.8 %     1,574       74.4 %

Gross profit

    1,856       61.2 %     543       25.6 %

Operating expenses:

                               

Sales and marketing

    1,547       51.0 %     2,226       105.1 %

Research and development

    323       10.6 %     232       11.0 %

General and administrative

    2,816       92.8 %     3,339       157.7 %

Acquisition related amortization expense

    970       32.0 %     870       41.1 %

Total operating expenses

    5,656       186.4 %     6,667       314.9 %
                                 

Operating loss

    (3,800 )     -125.2 %     (6,124 )     -289.3 %

Interest expense

    (204 )     -6.7 %     (848 )     -40.1 %

Other income (expense), net

    7       0.2 %     (86 )     -4.1 %

Loss from continuing operations before tax

    (3,997 )     -131.7 %     (7,058 )     -333.4 %

Provision (benefit) for income tax

    9       0.3 %     (73 )     -3.4 %

Loss from continuing operations

    (4,006 )     -132.0 %     (6,985 )     -329.9 %

(Loss) income from discontinued operations, net of tax

    (780 )     -25.7 %     3,117       147.2 %

Net loss

  $ (4,786 )     -157.7 %   $ (3,868 )     -182.7 %

 

 

 

Revenue, net

 

Consolidated revenue for the three months ended March 31, 2016 increased by $0.9 million, or 43.4%, to $3.0 million, compared to the three months ended March 31, 2015. This increase was principally attributable to the revenue generated from ThyGenX® and ThyraMIR® , which were both launched in the second quarter of 2015.

 

 

INTERPACE DIAGNOSTICS GROUP, INC. 

 

Cost of revenue

 

Consolidated cost of revenue for the three months ended March 31, 2016 decreased $0.4 million, or 25.1%, to $1.2 million, compared to the three months ended March 31, 2015. This decrease was attributable to the lower lab supplies expenses under a broad-based program to maximize efficiencies and cut costs.

 

Gross profit

 

Consolidated gross profit for the three months ended March 31, 2016 increased $1.3 million, or 241.8%, to $1.9 million, compared to the three months ended March 31, 2015. This increase was related to the favorable impact of the increase in cash-basis revenue along with the lower cost of revenue described above.

 

Sales and marketing expense

 

Sales and marketing expense was $1.5 million for the three months ended March 31, 2016 and as a percentage of revenue was 51.0%. For the three months ended March 31, 2015 the expense was $2.2 million and 105.1% as a percentage of revenue. The decrease in sales and marketing expense principally reflects a reduction in sales personnel and the consolidation of marketing activities under a broad-based program to maximize efficiencies and cut costs.

 

Research and development

 

Research and development expense was $0.3 million for the three months ended March 31, 2016, slightly higher than the first quarter of 2015, and as a percentage of revenue was 10.6%. For the three months ended March 31, 2015 the expense was $0.2 million.

 

General and administrative

 

General and administrative expense for the three months ended March 31, 2016 was $2.8 million as compared to $3.3 million for the three months ended March 31, 2015. This decrease was primarily attributable to downsizing of systems, infrastructure and personnel related to operating a smaller molecular diagnostics business under a broad-based program to maximize efficiencies and cut costs.

 

Acquisition related amortization expense

 

During the three months ended March 31, 2016, we recorded amortization expense of $1.0 million as compared to $0.9 million for the three months ended March 31, 2015. This relates to the amortization for RedPath and Asuragen acquired intangible assets.

 

Operating loss

 

There were operating losses from continuing operations of $3.8 million and $6.1 million during the three months ended March 31, 2016 and 2015, respectively.  The decrease in operating loss for the three months ended March 31, 2016 was primarily attributable to the favorable margins in addition to the cost savings initiated under our broad-based program to maximize efficiencies and cut costs.

 

Provision for income taxes

 

We had an income tax provision of approximately $9,000 for the three months ended March 31, 2016. We had an income tax benefit of approximately $0.1 million for the three months ended March 31, 2015. Income tax expense for the three months ended March 31, 2016 was due to minimum state and local taxes. The income tax benefit for the three months ended March 31, 2015 was primarily due to our operating loss.

 

Income (loss) from discontinued operations, net of tax

 

We had a loss from discontinued operations of $0.8 million for the three months ended March 31, 2016 as compared to income from discontinued operations of $3.1 million for the three months ended March 31, 2015. This decrease was primarily related to the sale of substantially all of our CSO business in 2015 and the winding down of the remaining CSO contracts during the first quarter of 2016.

 

 

INTERPACE DIAGNOSTICS GROUP, INC. 

 

LIQUIDITY AND CAPITAL RESOURCES 

 

For the three months ended March 31, 2016, we incurred a net loss of $4.8 million and cash used in operating activities was $4.0 million.  We did not raise any capital or incur any additional debt during the first quarter of 2016. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to ramping up our commercial operations, further developing our products and product candidates, right sizing and reorganizing our administrative organization and winding down activities and managing obligations related to our discontinued operations. The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2016, we had cash and cash equivalents of $4.3 million, net accounts receivable of $2.8 million and current liabilities of $19.7 million.

 

As a result of the sale of substantially all of our Commercial Services Organization (CSO) business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), we focused our resources and strategic initiatives on the molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, we will require additional capital in 2016 and beyond and in order to obtain such capital and fund our operations, we may be required to restructure all or a portion of our obligations related to the sale of our CSO business. There is, however, no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that are sufficient to fund our operations in 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to us. Accordingly, we are exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development and other sources. Additionally, we intend to help meet our capital needs by driving revenue growth of our commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, we are unsuccessful in executing our plan for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then we may be forced to seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure our business operations. These factors, among others, raise substantial doubt about our ability to continue as a going concern.

 

In March 2016, we announced that we implemented a broad-based program to maximize efficiencies and cut costs as we focus on improving cash flows and profitability while completing our transition to a standalone molecular diagnostics business. In addition to reducing headcount, we have realigned our compensation structure, consolidated positions, eliminated programs and development plans that did not have near term benefits and streamlined and right-sized operating systems while reducing overhead.

 

 

 INTERPACE DIAGNOSTICS GROUP, INC.

 

Management may be able to take additional steps to further reduce our future operating expenses, as needed.  However, we cannot provide any assurance that we will be able to raise additional capital as needed. A summary of our significant contractual obligations, as of March 31, 2016, over the next 12 months are as follows:

 

 

 

   

Total

   

0 to 3

months

   

3 to 6

months

   

6 to 12

months

 

Note due Redpath Equityholders

  $ 2,668     $ -     $ -     $ 2,668  

Severance obligations

    3,675       2,774       901       -  

DOJ settlement

    750       -       85       665 *

Asuragen Deferred Purchase Price

    500       300       200       -  

Total obligations

  $ 7,593     $ 3,074     $ 1,186     $ 3,333  

  

* Estimated liability based on our current revenue expectation.  

 

 

During the three months ended March 31, 2016, net cash used in operating activities was $4.0 million, of which $1.8 million was used in continuing operations and $2.2 million was used in discontinued operations.  The main component of cash used in operating activities during the three months ended March 31, 2016 was our loss from continuing operations of $4.0 million. During the three months ended March 31, 2015, net cash used in operating activities was $5.6 million, of which $11.7 million was used in continuing operations and $6.1 million was provided by discontinued operations. The main component of cash used in operating activities during the three months ended March 31, 2015 was our loss from continuing operations of $7.0 million and decreases in accounts receivable and accounts payable.

 

For the three months ended March 31, 2016 there was no net cash from investing activities. For the three months ended March 31, 2015 net cash used in investing activities was $0.5 million and consisted of purchases of property and equipment.

 

For the three months ended March 31, 2016 there was no net cash used in financing. For the three months ended March 31, 2015 the net cash used by financing activities of $0.03 million related to the repurchase of restricted stock shares.

 

As of March 31, 2016 we had total assets and total liabilities of $56.8 million and $48.5 million, respectively and current assets and current liabilities of $11.7 million and $19.7 million, respectively.

 

We had standby letters of credit of approximately $0.5 million and $1.4 million at March 31, 2016 and 2015, respectively, as collateral for our existing insurance policies and our facility leases.  In February 2016, we reduced our letters of credit by $0.6 million and received the same amount in cash as a return of our deposit due to the expiration of our building lease in Saddle River, NJ. Our standby letters of credit automatically renew every year unless canceled in writing by us with consent of the beneficiary, generally not less than 60 days before the expiry date.

 

Inflation 

 

We do not believe that inflation had a significant impact on our results of operations for the periods presented. On an ongoing basis, we attempt to minimize any effects of inflation on our operating results by controlling operating costs and, whenever possible, seeking to insure that billing rates reflect increases in costs due to inflation.

 

Off-Balance Sheet Arrangements

 

None.

 

 

INTERPACE DIAGNOSTICS GROUP, INC.

 

Item 4.  Controls and Procedures

 

Evaluation of disclosure controls and procedures 

 

Our management, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of the end of the period covered by this Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, management is required to apply its judgment in evaluating the benefits of possible disclosure controls and procedures relative to their costs to implement and maintain.

 

Based on our evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in internal controls

 

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 INTERPACE DIAGNOSTICS GROUP, INC.

 

PART II.  OTHER INFORMATION

 

Item 1.  Legal Proceedings  

 

“Item 3- Legal Proceedings” of our most recent Annual Report on Form 10-K filed on March 30, 2016 includes a discussion of our legal proceedings, as does Note 6 to the accompanying condensed consolidated financial statements. During the fiscal quarter ended March 31, 2016, there have been no material changes from the proceedings discussed in our Form 10-K except as follows:

 

 

Prolias Technologies, Inc. v. PDI, Inc.

 

 

On February 24, 2016, Prolias filed a motion before the New Jersey Appellate Division to appeal on an interlocutory basis the order denying the motion to disqualify our counsel. We filed our opposition to the motion on March 7, 2016. It is not known when the Appellate Division will rule on the motion for leave to take an interlocutory appeal, and further it is not known whether, if Prolias is successful in obtaining leave to appeal, what would be the result of the appeal. Progress on the case has been stayed pending resolution of this issue. In the interim, counsel for Prolias has filed for permission to withdraw as counsel, citing nonpayment of its bills. That motion also remains pending.

 

We deny that we are liable to Prolias for any of the claims asserted in the Complaint and we intend to (a) vigorously defend ourselves against those claims, (b) pursue all claims asserted in the Counterclaim and (c) vigorously oppose the motion for leave to appeal.

 

 

 

Item 6.  Exhibits

 

Exhibit No.

 

Description

     
     

10.1

 

Agreement and General Release, dated January 6, 2016, by and between Gerald Melillo and PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.) is incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 11, 2016.

     

10.2

 

Agreement and General Release, dated January 15, 2016, by and between Nancy S. Lurker and PDI, Inc. (n.k.a. Interpace Diagnostics Group, Inc.) is incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 22, 2016.

     

10.3

 

Severance Agreement and General Release, dated March 28, 2016, by and between Graham Miao and Interpace Diagnostics Group, Inc. is incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on March 29, 2016.

     

31.1

 

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

     

31.2

 

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

     

32.1*

 

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

     

32.2*

 

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

     

101

 

The following financial information from this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) the Notes to Condensed Consolidated Financial Statements.

 

 

*

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference to any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

 

 

 INTERPACE DIAGNOSTICS GROUP, INC.

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date:

May 11, 2016

 Interpace Diagnostics Group, Inc.

 
   

(Registrant)

 
       
   

/s/ Jack E. Stover

 
   

Jack E. Stover

 
   

Interim President and Chief Executive Officer and Director

 
   

(Principal Executive Officer)

 
       
   

/s/ Nat Krishnamurti

 
   

Nat Krishnamurti

 
   

Chief Financial Officer, Treasurer and Secretary

 
   

(Principal Financial Officer and Principal Accounting Officer)

 

 

 

28

EX-31.1 2 ex31-1.htm EXHIBIT 31.1 ex31-1.htm

 

Exhibit 31.1

 

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jack E. Stover, certify that:

 

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 of Interpace Diagnostics Group, Inc. (the “registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:   May 11, 2016

/s/ Jack E. Stover

   

Interim Chief Executive Officer

   

(Principal Executive Officer)

 

 

 

 

EX-31.2 3 ex31-2.htm EXHIBIT 31.2 ex31-2.htm

Exhibit 31.2

 

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Nat Krishnamurti, certify that:

 

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 of Interpace Diagnostics Group, Inc. (the “registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:   May 11, 2016

/s/ Nat Krishnamurti

   

Chief Financial Officer

   

(Principal Financial Officer)

     

 

 

 

EX-32.1 4 ex32-1.htm EXHIBIT 32.1 ex32-1.htm

Exhibit 32.1

 

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

 

In connection with the Quarterly Report of Interpace Diagnostics Group, Inc. (the “Company”) on form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack E. Stover, as Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:   May 11, 2016

/s/ Jack E. Stover

   

Interim Chief Executive Officer

   

(Principal Executive Officer)

 

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

EX-32.2 5 ex32-2.htm EXHIBIT 32.2 ex32-2.htm

 

Exhibit 32.2

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

 

In connection with the Quarterly Report of Interpace Diagnostics Group, Inc. (the “Company”) on form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nat Krishnamurti, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

 

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:   May 11, 2016

/s/ Nat Krishnamurti

   

Chief Financial Officer

   

(Principal Financial Officer)

 

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

EX-101.INS 6 idxg-20160331.xml EXHIBIT 101.INS false --12-31 Q1 2016 2016-03-31 10-Q 0001054102 18162671 Yes Smaller Reporting Company Interpace Diagnostics Group, Inc. No No idxg 4600000 13900000 500000 1000000 901 85 200 1186 2668 665 3333 2774 300 3074 1333750 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="10"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Three Months Ended</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="10"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Year Ended</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">735 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">735 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unbilled receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">795 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">795 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,530 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,530 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property and equipment, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long-term assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">183 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,713 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 18%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,195 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,195 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unearned contract revenue</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued salary and bonus</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,812 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">288 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,100 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,092 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,450 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current liabilities from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">6,226 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">288 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">6,514 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,226 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">288 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,514 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> 2219000 2219000 3036000 3036000 344000 360000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom" width="581">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 21%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6" width="324"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ending March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom" width="581">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2" width="155"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2" width="155"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Revenue, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">1,644 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">36,463 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="WIDTH: 61%; BACKGROUND-COLOR: #ffffff" width="581">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 16%; BACKGROUND-COLOR: #ffffff" width="148">&nbsp;</td> <td style="WIDTH: 2%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 16%; BACKGROUND-COLOR: #ffffff" width="148">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, before tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">(735</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">)*</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">3,118 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax expense</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="148">45 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="148">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, net of tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">(780</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">3,117 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> </tr> </table></div> 544000 546000 1245000 1560000 2780000 2806000 16000 35000 203000 261000 6655000 5961000 1084000 775000 13000 125800000 132522000 970000 870000 -6100000 -6800000 100000 200000 900000 970000 870000 25 1027 1066 1317 1632 188 2344 2911 56775000 67712000 11674000 19165000 1563000 150000 1713000 5564000 150000 5714000 1530000 1530000 5374000 5374000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">3.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Accounting Estimates</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-style: italic;"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.&nbsp;&nbsp;Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. &nbsp;The Company periodically reviews these matters and reflects changes in estimates as appropriate.&nbsp;&nbsp;Actual results could materially differ from those estimates.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Commercial Services business in the period ended March 31, 2015 has been reclassified to discontinued operations to conform to the current period presentation.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Receivables and Allowance for Doubtful Accounts </div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s accounts receivable are generated using its proprietary tests. The Company&#x2019;s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen&reg; hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp; </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which&nbsp;may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $0.9 million allowance for doubtful accounts as of March 31, 2016.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Current Assets</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other current assets consisted of the following as of March 31, 2016 and December 31, 2015:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,375 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Letters of credit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">344 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">360 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other receivables</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">960 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,048 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prepaid expenses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">243 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">180 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">102 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">106 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,024 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,569 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Intangible Assets</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Discontinued Operations</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for business dispositions and its businesses held for sale in accordance with ASC&nbsp;205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note&nbsp;11, <div style="display: inline; font-style: italic;">Discontinued Operations</div> for further information.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Basic and Diluted Net Loss per Share</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2016 and 2015 is as follows:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic weighted average number&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,762 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,037 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Potential dilutive effect of stock-based awards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diluted weighted average number</div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,762 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,037 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-settled stock appreciation rights (SARs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,066 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock and restricted stock units (RSUs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,317 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,632 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Performance contingent SARs</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,344 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,911 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> 500000 500000 500000 500000 10700000 7500000 4628000 4628000 4628000 13921000 13921000 13921000 659000 659000 17890000 17890000 2500000 500000 1500000 4340000 8310000 23111000 17004000 3564000 3564000 3564000 776000 776000 776000 4340000 4340000 4340000 -3970000 -6107000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">13. </div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">S</div><div style="display: inline; font-weight: bold;">UPPLEMENTAL CASH FLOW INFORMATION</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table represents cash flows (used in) provided by the Company's discontinued operations for the three months ended March 31, 2016 and 2015:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For The Three Months Ended March 31</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash (used in) provided by operating activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">(2,171</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,073</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash provided by (used in) investing activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> -2171000 6073000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">6</div><div style="display: inline; font-weight: bold;">.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">COMMITMENTS AND CONTINGENCIES </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Letters of Credit</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March&nbsp;31, 2016, the Company had $0.5 million in letters of credit outstanding as required by its existing insurance policies and its facility leases. These letters of credit are collateralized by certain investments.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp; </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Contingency</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace Diagnostics, LLC (Interpace LLC) entered into a Contingent Consideration Agreement with RedPath Equityholder Representative, LLC (the&nbsp;Equityholder Representative). Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company&#x2019;s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG&reg; for the management of Barrett&#x2019;s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen&#x2122; for predicting risk of progression from Barrett&#x2019;s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its Commercial Services (CSO) business in December 2015, decreasing the balance in Treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Litigation</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company&#x2019;s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company&#x2019;s liability exceeds the amount of applicable insurance or indemnity.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of March 31, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (&#x201c;DOJ&#x201d;). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for up to $2.5 million of the obligation, with the first $0.5 million payable by the Company. At March 31, 2016, the Company has recorded an indemnification asset of $1.5 million of which $0.5 is included in <div style="display: inline; font-style: italic;">other current assets</div> and $1.0 million is included in <div style="display: inline; font-style: italic;">other non-current assets</div>. At March 31, 2016, the Company has $1.8 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.8 million is included in<div style="display: inline; font-style: italic;"> </div><div style="display: inline; font-style: italic;">other accrued expenses</div> and $1.0 million is included in <div style="display: inline; font-style: italic;">other long-term liabilities</div>. In May 2016, the Company negotiated a payment plan with the DOJ to pay the $250,000 currently due based on its 2015 revenues in three relatively equal installments in August 2016, October 2016 and February 2017.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Prolias Technologies, Inc. v. PDI, Inc. </div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On April 8, 2015, Prolias Technologies, Inc., or Prolias, filed a complaint (the Complaint) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled&nbsp;Prolias Technologies, Inc. v. PDI, Inc.&nbsp;(Docket No. MRS-L-899-15). &nbsp;In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto, collectively the Agreement, whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as &quot;Thymira.&quot; &nbsp;Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied liability for the claims being asserted in the Complaint. In the Counterclaim, the Company asserted claims against Prolias for breaches of the Agreement and for a declaratory judgment. The Company seeks damages from Prolias in excess of $500,000 plus interest and attorney&#x2019;s fees and costs, together with a declaration compelling Prolias to execute and deliver to the Company a promissory note in the amount of One Million Five Hundred Thousand Dollars ($1,500,000.00) to evidence Prolias&#x2019; obligation to repay the Company for amounts that were advanced. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">After the Answer and Counterclaim were filed, the Company and Prolias exchanged paper discovery. &nbsp;In early December 2015, Prolias replaced its counsel with new counsel. &nbsp;Thereafter, on December 18, 2015, Prolias filed an Order to Show Cause and Temporary Restraining Order (TRO) that sought to (a) enjoin the Company from selling the assets that comprise its CSO business to Publicist Healthcare Communications Group and (b) disqualify the Company's counsel from representing it in the litigation.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On December 21, 2015, the Court held a hearing on Prolias's application to temporarily enjoin the sale of the CSO business. Following the hearing the Court denied Prolias's application for a TRO and set a hearing date on the motions to disqualify counsel and to obtain an injunction.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 4, 2016, the Court heard argument on Prolias's motions to disqualify the Company&#x2019;s counsel and to obtain an injunction with respect to the CSO sale. Following the hearing, the Court entered orders denying the motion to disqualify and denying the motion for an injunction.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 24, 2016, Prolias filed a motion before the New Jersey Appellate Division to appeal on an interlocutory basis the order denying the motion to disqualify. &nbsp;The Company filed its opposition to the motion on March 7, 2016. &nbsp;It is not known when the Appellate Division will rule on the motion for leave to take an interlocutory appeal, and further it is not known whether, if Prolias is successful in obtaining leave to appeal, what would be the result of the appeal. Progress on the case has been stayed pending resolution of this issue. In the interim, counsel for Prolias has filed for permission to withdraw as counsel, citing nonpayment of its bills. That motion also remains pending. </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company denies that it is liable to Prolias for any of the claims asserted in the Complaint and it intends to (a) vigorously defend itself against those claims, (b) pursue all claims asserted in the Counterclaim and (c) vigorously oppose the motion for leave to appeal.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Severance</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In 2015, in connection with the sale of substantially all of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to $3.7 million. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the three month period ended March 31, 2016 the Company recorded additional severance obligations as it discontinued the remainder of its CSO business and recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations within general and administrative expenses in the Condensed Consolidated Statement of Comprehensive Loss. A rollforward of the severance activity is as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Continuing </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Discontinued</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,011 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,074 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,085 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accruals</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">459 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,118 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payments</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(140</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(388</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(528</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,330 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,345 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,675 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 0.01 0.01 0.01 100000000 100000000 18705214 18705214 18162671 17662671 187000 187000 -4786000 -3868000 2668 3675 750 500 7593 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">0 to 3 </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3 to 6 </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6 to 12 </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note due Redpath Equityholders </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,668 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,668 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Severance obligations </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,675 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,774 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">901 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Department of Justice (&quot;DOJ&quot;) settlement</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">750 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">85 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">665 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">*</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen Deferred Purchase Price</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">500 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">300 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7,593 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,074 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,186 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,333 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> 1179000 1574000 11000000 20000000 0.05 2100000 104000 127000 27000 52000 1257000 1195000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">8</div><div style="display: inline; font-weight: bold;">.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">STOCK-BASED COMPENSATION</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In 2015, the Board and stockholders approved the Company&#x2019;s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company&#x2019;s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan.&nbsp;&nbsp;The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan.&nbsp;&nbsp;Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee.&nbsp;&nbsp;Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for issuance under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder.&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant.&nbsp;&nbsp;The restricted shares and restricted stock units (RSU&#x2019;s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, certain employees and members of the Company&#x2019;s Board of Directors were granted approximately 1.3 million RSU&#x2019;s at a weighted average grant price of $0.25.&nbsp;These shares vest one-third each year on the anniversary of the date of grant.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the three month periods ended March 31, 2016 and March 31, 2015:&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ending</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">0.97%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">3.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">52.03%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recognized approximately $0.1 million and $0.2 million of stock-based compensation expense during each of the three month periods ended March 31, 2016 and 2015, respectively.</div></div> -735000 3118000 45000 1000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Discontinued Operations</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for business dispositions and its businesses held for sale in accordance with ASC&nbsp;205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note&nbsp;11, <div style="display: inline; font-style: italic;">Discontinued Operations</div> for further information.</div></div></div></div></div></div></div></div> 16000 16000 2195000 2195000 3767000 3767000 33000 150000 183000 190000 150000 340000 11000 11000 -780000 3117000 795000 795000 2062000 2062000 1812000 288000 2100000 5092000 358000 5450000 150000 150000 150000 150000 33000 33000 190000 190000 1644000 36463000 285000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">11.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">DISCONTINUED OPERATIONS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The table below presents the significant components of Commercial Services, Group DCA's, Pharmakon's and TVG&#x2019;s results included in Loss from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the years ended March&nbsp;31, 2016 and 2015.</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom" width="581">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 21%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6" width="324"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ending March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom" width="581">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2" width="155"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2" width="155"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Revenue, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">1,644 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">36,463 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="WIDTH: 61%; BACKGROUND-COLOR: #ffffff" width="581">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 16%; BACKGROUND-COLOR: #ffffff" width="148">&nbsp;</td> <td style="WIDTH: 2%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="WIDTH: 16%; BACKGROUND-COLOR: #ffffff" width="148">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, before tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">(735</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">)*</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">3,118 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax expense</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="148">45 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="148">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap" width="7">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 61%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="581"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income from discontinued operations, net of tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">(780</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="148">3,117 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap" width="7">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 28.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">* Approximately $659,000 of the balance relates to severance relating to terminated employees. </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The assets and liabilities classified as discontinued operations relate to Commercial Services, Group DCA, Pharmakon, and TVG. As of March&nbsp;31, 2016 and December&nbsp;31, 2015, these assets and liabilities are in the accompanying balance sheets as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="10"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Three Months Ended</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="10"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the Year Ended</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CSO</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DCA/</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">TVG</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">735 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">735 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,296 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unbilled receivable, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">795 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">795 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,062 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,530 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,530 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,374 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property and equipment, net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long-term assets from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">183 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">190 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,713 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">150 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">5,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 18%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 10%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,195 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,195 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,767 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unearned contract revenue</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">11 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued salary and bonus</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,812 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">288 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,100 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,092 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,450 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current liabilities from discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">6,226 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">288 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">6,514 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total liabilities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,226 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">288 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,514 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">11,906 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">358 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">12,264 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> -0.27 -0.26 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Basic and Diluted Net Loss per Share</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2016 and 2015 is as follows:</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic weighted average number&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,762 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,037 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Potential dilutive effect of stock-based awards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diluted weighted average number</div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,762 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,037 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-settled stock appreciation rights (SARs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,066 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock and restricted stock units (RSUs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,317 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,632 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Performance contingent SARs</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,344 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,911 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div></div></div> 0.002 0.01 2869000 2424000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 29%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value Measurements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Marketable securities:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Treasury securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">553 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">553 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">553 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">5.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">FAIR VALUE MEASUREMENTS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 68pt">&nbsp;</td> <td style="WIDTH: 40pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1:</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 68pt">&nbsp;</td> <td style="WIDTH: 40pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2:</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.</div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 68pt">&nbsp;</td> <td style="WIDTH: 40pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3:</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.</div></div></td> </tr> </table> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 15%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 29%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair Value Measurements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Fair</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="11"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Money market funds</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">776 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,340 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Marketable securities:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Treasury securities</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">553 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">553 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">553 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liabilities:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,628 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">13,921 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,549 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of March 31, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3). </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the acquisition of assets from Asuragen and the acquisition of RedPath, the Company has recorded $4.6 million and $13.9 million of contingent cash consideration related to deferred payments and revenue based payments, respectively. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&nbsp;3 measurement.&nbsp; There was no change in the fair value of the contingent consideration during the period ended March 31, 2016.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.&nbsp;&nbsp;There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain of the Company's non-financial assets, such as other intangible assets,&nbsp;are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.</div></div> P9Y P7Y P4Y P7Y P9Y P2Y109D 5555000 4889000 5703000 5703000 5949000 6097000 8519000 2882000 1575000 16141000 18351000 47468000 609000 42522000 2816000 3339000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">4.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">OTHER INTANGIBLE ASSETS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The net carrying value of the identifiable intangible assets as of March 31, 2016 is as follows:&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Life</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thyroid</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,519 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,882 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Biobank</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,575 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">16,141 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Barrett's test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">47,468 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic lab:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CLIA Lab</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">2.3</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">609 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(5,555</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net Carrying Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">42,522 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization expense was $1.0 million and $0.9 million for the three month periods ended March 31, 2016 and 2015, respectively. Amortization of the Company's diagnostic assets begin upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches: </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,889 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,097 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,949 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,703 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,703 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Other Intangible Assets</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.</div></div></div></div></div></div></div></div> 1856000 543000 -4006000 -6985000 -3997000 -7058000 -0.23 -0.46 -0.04 0.21 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">9.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">INCOME TAXES </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.&nbsp; As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.&nbsp; The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- month periods ended March 31, 2016 and 2015:&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Provision (benefit) for income tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">9 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">(73</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective income tax rate </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">0.2</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax expense for the quarter ended March 31, 2016 was due to minimum state and local taxes. Income tax benefit for the quarter ended March 31, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.</div></div> 9000 -73000 -1887000 -1274000 -4270000 5229000 -2566000 -4602000 -372000 1040000 -11000 4144000 460000 438000 -689000 -2156000 -482000 336000 -16000 -420000 200000 200000 203000 848000 818000 553000 553000 553000 18549000 18549000 18549000 500000 48469000 54674000 56775000 67712000 19746000 23373000 4696000 6178000 6226000 288000 6514000 11906000 358000 12264000 6226000 288000 6514000 11906000 358000 12264000 875000 875000 3468000 3425000 3000000 250000 8600000 2463000 1164000 4001000 5335000 1334000 6137000 7233000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">12.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">LONG-TERM DEBT </div></div></div></td> </tr> </table> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the Equityholder Representative, dated October 31, 2014 (as amended, the Note).</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Note is for $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October&nbsp;1, 2016. In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In October 2015, in connection with the sale of substantially all of the CSO business in December 2015, the Note was amended to, among other things:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#x25cf;</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">permit the Company to enter into a revolving loan facility,</div></div></td> </tr> <tr> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#x25cf;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">permit the Company to sell the CSO business and to use the proceeds of the CSO sale to pay off the amounts due under the existing $20 million Credit Agreement and to continue to </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">make payments on the debt due under the Note in accordance with the terms of the Note</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">,</div></div></td> </tr> <tr> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#x25cf;</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">provide that, upon written request by the Equityholder Representative on April 30, 2016, the Company would make a one-time principal payment in the amount of $1,333,750 on July 1, 2016 rather than as originally due on July 1, 2018 (which such request the Company did not receive), and </div></div></td> </tr> <tr> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 18pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 7.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#x25cf;<div style="display: inline; font-style: italic;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 7.5pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">provide that the 500,000 shares of the Company&#x2019;s common stock to be issued upon the commercial launch of PancraGen&reg; for the management of Barrett&#x2019;s esophagus would be deemed earned by the former RedPath Equityholders as of the closing of the sale of the CSO business (see Note 6, <div style="display: inline; font-style: italic;">Commitments and Contingencies</div>). </div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries in favor of the Equityholder Representative. Pursuant to the guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended March 31, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. As of March&nbsp;31, 2016, the balance of the Note is approximately $8.6 million and the unamortized discount is $2.1 million.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Principal payments due related to the long-term debt over next three years are as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 39.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,334</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,335</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">4,001</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"> </div></div></div> </div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;<div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As discussed in Footnote 6, the Company currently has an indemnification asset and liability of $1.5 million ($0.5 million short-term and $1.0 million long-term) relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. As the Company makes payments to the DOJ, it may reduce the balance owed on the note by the same amount. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, the Company entered into the Credit Agreement with the Agent and the Lenders, as defined in the agreement, in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the loan was October&nbsp;31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Upon the sale of substantially all of the Commercial Services (CSO) business on December 22, 2015, the Company was obligated to use a portion of the net proceeds from the transaction to pay the balance of the outstanding Loan in the aggregate principal amount of $20.0 million, an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015.</div></div> 500000 -26000 -464000 -3970000 -5617000 -4786000 -3868000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">14. </div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">RECENT ACCOUNTING PRONOUNCEMENTS</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance permits the use of either a retrospective or cumulative effect transition method. In July 2015, the FASB approved a one-year deferral of the effective date of the guidance to interim and annual periods beginning on or after December 15, 2017. Early adoption is permitted but not before the original effective date of December 15, 2016. The Company has not yet selected a transition method and is currently evaluating the impact of the amended guidance on the Company&#x2019;s consolidated financial position, results of operations and related disclosures.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the FASB issued guidance on determining when and how to disclose going-concern uncertainties in&nbsp;financial statements. The new standard requires management to perform interim and annual assessments of an entity&#x2019;s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">consolidated financial position, results of operations and related disclosures.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In March 2016, the FASB issued guidance </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">which clarifies the implementation guidance on principal versus agent considerations in the revenue recognition standard issued in May 2014. The new standard clarifies how an entity should identify the unit of accounting (i.e. the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The effective date and transition requirements are the same as the effective date and transition requirements in the May 2014 revenue standard (Accounting Standards Codification 606). The Company is currently assessing the adoption methodology and the impact the adoption of these ASUs will have on its </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">consolidated financial position, results of operations and related disclosures.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance permits the use of either a retrospective or cumulative effect transition method. In July 2015, the FASB approved a one-year deferral of the effective date of the guidance to interim and annual periods beginning on or after December 15, 2017. Early adoption is permitted but not before the original effective date of December 15, 2016. The Company has not yet selected a transition method and is currently evaluating the impact of the amended guidance on the Company&#x2019;s consolidated financial position, results of operations and related disclosures.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the FASB issued guidance on determining when and how to disclose going-concern uncertainties in&nbsp;financial statements. The new standard requires management to perform interim and annual assessments of an entity&#x2019;s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">consolidated financial position, results of operations and related disclosures.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In March 2016, the FASB issued guidance </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">which clarifies the implementation guidance on principal versus agent considerations in the revenue recognition standard issued in May 2014. The new standard clarifies how an entity should identify the unit of accounting (i.e. the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The effective date and transition requirements are the same as the effective date and transition requirements in the May 2014 revenue standard (Accounting Standards Codification 606). The Company is currently assessing the adoption methodology and the impact the adoption of these ASUs will have on its </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">consolidated financial position, results of operations and related disclosures.</div></div></div></div> 1500000 1 5656000 6667000 -3800000 -6124000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">BASIS OF PRESENTATION </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc. </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC, </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">and related notes as included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016.&nbsp;&nbsp;The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.&nbsp;&nbsp;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&nbsp;&nbsp;The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.&nbsp;&nbsp;All significant intercompany balances and transactions have been eliminated in consolidation.&nbsp;&nbsp;Discontinued operations include the Company's wholly-owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services business unit. All significant intercompany balances and transactions have been eliminated in consolidation. </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operating results for the three-month period ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2016.</div></div></div> 1951000 1958000 102000 106000 3024000 2569000 1066000 3255000 42522000 43492000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">7.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">ACCRUED EXPENSES AND LONG-TERM LIABILITIES</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other accrued expenses consisted of the following as of March 31, 2016 and December&nbsp;31, 2015:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Facilities realignment accrual</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">43 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Self insurance accruals</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">66 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">137 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">104 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">127 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">750 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued professional fees</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,084 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">775 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Taxes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">622 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">591 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unclaimed property</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">544 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">546 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All others</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,951 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,958 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,655 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long-term liabilities consisted of the following as of March 31, 2016 and December&nbsp;31, 2015:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">27 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">52 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Uncertain tax positions</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,468 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,425 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement (indemnified by RedPath)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,500 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">201 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">201 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">4,696 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 201000 201000 13000 6000 -86000 960000 1048000 1600000 26000 140000 388000 528000 464000 0.01 0.01 5000000 5000000 0 0 0 0 243000 180000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Commercial Services business in the period ended March 31, 2015 has been reclassified to discontinued operations to conform to the current period presentation.</div></div></div></div></div></div></div></div> 19600000 26800000 1330000 1460000 89000 96000 1375000 875000 1800000 800000 1000000 1000000 2500000 21600000 323000 232000 459000 659000 1118000 2011000 1074000 3085000 2330000 1345000 3675000 43000 -116038000 -111252000 3035000 2117000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Facilities realignment accrual</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">43 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Self insurance accruals</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">66 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">137 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification liability</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Contingent consideration</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">104 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">127 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">750 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued professional fees</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,084 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">775 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Taxes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">622 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">591 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unclaimed property</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">544 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">546 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All others</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,951 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1,958 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,655 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,961 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Life</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic assets:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thyroid</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,519 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,882 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Biobank</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,575 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">RedPath acquisition:</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pancreas test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">16,141 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Barrett's test</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">9</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">18,351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">47,468 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Diagnostic lab:</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CLIA Lab</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">2.3</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">609 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(5,555</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net Carrying Value</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">42,522 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-settled stock appreciation rights (SARs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,027 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,066 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Restricted stock and restricted stock units (RSUs)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,317 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,632 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Performance contingent SARs</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">188 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,344 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,911 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For The Three Months Ended March 31</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash (used in) provided by operating activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">(2,171</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,073</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net cash provided by (used in) investing activities of discontinued operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="4"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 39.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,334</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5,335</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">4,001</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Provision (benefit) for income tax</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">9 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">(73</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective income tax rate </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">0.2</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">% </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">27 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">52 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Uncertain tax positions</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,468 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,425 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DOJ settlement (indemnified by RedPath)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,500 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">201 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">201 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">4,696 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,178 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 66%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,375 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">875 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Letters of credit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">344 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">360 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other receivables</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">960 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,048 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prepaid expenses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">243 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">180 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">102 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">106 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,024 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,569 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Continuing </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Discontinued</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of December 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,011 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,074 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,085 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accruals</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">459 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">659 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,118 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payments</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(140</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(388</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(528</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance as of March 31, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,330 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,345 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,675 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ending</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">0.97%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">3.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">52.03%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 31,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic weighted average number&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,762 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,037 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Potential dilutive effect of stock-based awards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diluted weighted average number</div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of common shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">17,762 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">15,037 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">4,889 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,097 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,949 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,703 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,703 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">10.</div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">SEGMENT INFORMATION</div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective December&nbsp;31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its Commercial Services business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company's molecular diagnostics business&nbsp;focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.</div></div></div> 66000 137000 1547000 2226000 750000 250000 3700000 1100000 500000 659000 67000 396000 P3Y P3Y 1.3 0.25 0 0.5203 0.0097 2450000 0.3333 0.3333 P5Y P3Y182D 106000 6100000 6800000 8306000 13038000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2.</div><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">LIQUIDITY AND MANAGEMENT'S PLANS </div></div></div></td> </tr> </table> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the three months ended March 31, 2016, the Company incurred a net loss of $4.8 million and cash used in operating activities was $4.0 million. &nbsp;The Company did not raise any capital or incur any additional debt during the first quarter of 2016. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to ramping up its commercial operations, further developing its products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations. The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2016, the Company had cash and cash equivalents of $4.3 million, net accounts receivable of $2.8 million and current liabilities of $19.7 million. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result of the sale of substantially all of its Commercial Services Organization (CSO) business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on the molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company will require additional capital in 2016 and beyond and in order to obtain such capital and fund its operations, may be required to restructure all or a portion of its obligations related to the sale of its CSO business. There is, however, no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that is sufficient to fund the Company's operations in 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development and other sources. Additionally, the Company intends to help meet its capital needs by driving revenue growth of our commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. These factors, among others, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A summary of the Company&#x2019;s significant contractual obligations as of March 31, 2016 over the next 12 months are as follows:</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">0 to 3 </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3 to 6 </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6 to 12 </div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">months</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Note due Redpath Equityholders </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,668 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,668 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Severance obligations </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">3,675 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">2,774 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">901 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Department of Justice (&quot;DOJ&quot;) settlement</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">750 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">85 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">665 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">*</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Asuragen Deferred Purchase Price</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">500 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">300 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7,593 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,074 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,186 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,333 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25">* Estimated liability based on our current revenue expectation.<div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></div> 622000 591000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Receivables and Allowance for Doubtful Accounts </div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s accounts receivable are generated using its proprietary tests. The Company&#x2019;s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen&reg; hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.</div></div><div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp; </div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which&nbsp;may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $0.9 million allowance for doubtful accounts as of March 31, 2016.</div></div></div></div></div></div></div></div> 735000 735000 3296000 3296000 542543 1042543 1643000 8432000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Accounting Estimates</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-style: italic;"></div>&nbsp;</div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 36pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.&nbsp;&nbsp;Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals. &nbsp;The Company periodically reviews these matters and reflects changes in estimates as appropriate.&nbsp;&nbsp;Actual results could materially differ from those estimates.</div></div></div></div></div></div></div></div> 17762000 15037000 17762000 15037000 Estimated liability based on our current revenue expectation. Approximately $659,000 of the balance relates to severance relating to terminated employees. iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares 0001054102 2014-10-31 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:LoansPayableMember 2014-10-31 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:NotesPayableOtherPayablesMember 2014-10-31 2014-10-31 0001054102 2015-01-01 2015-03-31 0001054102 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001054102 us-gaap:PerformanceSharesMember 2015-01-01 2015-03-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-03-31 0001054102 us-gaap:StockAppreciationRightsSARSMember 2015-01-01 2015-03-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:NotesPayableOtherPayablesMember 2015-01-01 2015-03-31 0001054102 2015-01-01 2015-12-31 0001054102 idxg:RsusAndRestrictedStockMember 2015-01-01 2015-12-31 0001054102 idxg:RsusAndRestrictedStockMember us-gaap:DirectorMember 2015-01-01 2015-12-31 0001054102 us-gaap:StockAppreciationRightsSARSMember 2015-01-01 2015-12-31 0001054102 idxg:RedpathIntegratedPathologyIncMember 2015-04-01 2015-06-30 0001054102 2015-06-03 2015-06-03 0001054102 2015-06-16 2015-06-16 0001054102 idxg:RedpathIntegratedPathologyIncMember 2015-10-01 2015-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:LoansPayableMember 2015-10-01 2015-10-31 0001054102 2015-12-01 2015-12-31 0001054102 2015-12-22 2015-12-22 0001054102 2016-01-01 2016-03-31 0001054102 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001054102 us-gaap:PerformanceSharesMember 2016-01-01 2016-03-31 0001054102 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0001054102 us-gaap:StockAppreciationRightsSARSMember 2016-01-01 2016-03-31 0001054102 idxg:AsuragenAndRedpathMember 2016-01-01 2016-03-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestBiobankMember 2016-01-01 2016-03-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestPancreasMember 2016-01-01 2016-03-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestThyroidMember 2016-01-01 2016-03-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:NotesPayableOtherPayablesMember 2016-01-01 2016-03-31 0001054102 idxg:RedpathMember idxg:DiagnosticTestBarrettsRedpathMember 2016-01-01 2016-03-31 0001054102 idxg:RedpathMember idxg:DiagnosticTestPancreasMember 2016-01-01 2016-03-31 0001054102 idxg:CLIADiagnosticLabMember 2016-01-01 2016-03-31 0001054102 us-gaap:EmployeeSeveranceMember 2016-01-01 2016-03-31 0001054102 us-gaap:EmployeeSeveranceMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0001054102 us-gaap:EmployeeSeveranceMember us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-03-31 0001054102 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0001054102 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-03-31 0001054102 idxg:RsusAndRestrictedStockMember us-gaap:DirectorMember 2016-02-01 2016-02-29 0001054102 idxg:RsusAndRestrictedStockMember us-gaap:DirectorMember 2016-02-29 2016-02-29 0001054102 2016-03-01 2016-03-31 0001054102 us-gaap:SubsequentEventMember 2016-05-01 2016-05-31 0001054102 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:LoansPayableMember 2014-10-31 0001054102 idxg:RedpathIntegratedPathologyIncMember us-gaap:NotesPayableOtherPayablesMember 2014-10-31 0001054102 idxg:FormerOwnersOfRedpathMember 2014-10-31 0001054102 2014-12-31 0001054102 2015-03-31 0001054102 2015-12-31 0001054102 idxg:CommercialServicesMember 2015-12-31 0001054102 idxg:OtherDiscontinuedOperationsMember 2015-12-31 0001054102 us-gaap:EmployeeSeveranceMember 2015-12-31 0001054102 us-gaap:EmployeeSeveranceMember us-gaap:SegmentContinuingOperationsMember 2015-12-31 0001054102 us-gaap:EmployeeSeveranceMember us-gaap:SegmentDiscontinuedOperationsMember 2015-12-31 0001054102 2016-03-31 0001054102 idxg:OtherAccruedExpensesMember 2016-03-31 0001054102 us-gaap:OtherNoncurrentLiabilitiesMember 2016-03-31 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel1Member 2016-03-31 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel2Member 2016-03-31 0001054102 idxg:AsuragenMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001054102 idxg:AsuragenMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 idxg:AsuragenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestBiobankMember 2016-03-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestPancreasMember 2016-03-31 0001054102 idxg:AsuragenMember idxg:DiagnosticTestThyroidMember 2016-03-31 0001054102 idxg:InterpaceDiagnosticsLLCMember 2016-03-31 0001054102 idxg:RedpathIntegratedPathologyIncMember 2016-03-31 0001054102 idxg:RedpathMember 2016-03-31 0001054102 idxg:RedpathMember us-gaap:FairValueInputsLevel1Member 2016-03-31 0001054102 idxg:RedpathMember us-gaap:FairValueInputsLevel2Member 2016-03-31 0001054102 idxg:RedpathMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001054102 idxg:RedpathMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 idxg:RedpathMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001054102 idxg:RedpathMember idxg:DiagnosticTestBarrettsRedpathMember 2016-03-31 0001054102 idxg:RedpathMember idxg:DiagnosticTestPancreasMember 2016-03-31 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2016-03-31 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member 2016-03-31 0001054102 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001054102 us-gaap:CashMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:CashMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-03-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-03-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:FairValueInputsLevel1Member 2016-03-31 0001054102 us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2016-03-31 0001054102 us-gaap:FairValueInputsLevel2Member 2016-03-31 0001054102 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2016-03-31 0001054102 us-gaap:FairValueInputsLevel3Member 2016-03-31 0001054102 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2016-03-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2016-03-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0001054102 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:USTreasurySecuritiesMember 2016-03-31 0001054102 idxg:CLIADiagnosticLabMember 2016-03-31 0001054102 idxg:CommercialServicesMember 2016-03-31 0001054102 idxg:OtherDiscontinuedOperationsMember 2016-03-31 0001054102 idxg:DojSettlementMember 2016-03-31 0001054102 us-gaap:NotesPayableOtherPayablesMember 2016-03-31 0001054102 us-gaap:EmployeeSeveranceMember 2016-03-31 0001054102 us-gaap:EmployeeSeveranceMember us-gaap:SegmentContinuingOperationsMember 2016-03-31 0001054102 us-gaap:EmployeeSeveranceMember us-gaap:SegmentDiscontinuedOperationsMember 2016-03-31 0001054102 2016-05-06 EX-101.SCH 7 idxg-20160331.xsd EXHIBIT 101.SCH 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Liquidity and Management's Plans link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Other Intangible Assets link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Segment Information link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Discontinued Operations link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 018 - Document - Note 13 - Supplemental Cash Flow Information link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Recent Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 2 - Liquidity and Management's Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Other Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 6 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 8 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 9 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 11 - Discontinued Operations (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 12 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 13 - Supplemental Cash Flow Information (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Liquidity and Management's Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Contractual Obligations Due in the Next 12 Months (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 3 - Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 3 - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Other Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 4 - Identifiable Intangible Assets Carrying Value (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 4 - Future Estimated Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 5 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 5 - Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 6 - Severance Activity (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 7 - Oher Long-term Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 8 - Weighted Average Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 9 - Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 10 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 11 - Discontinued Operations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 11 - Results Included in Loss From Discontinued Operations, Net of Tax (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 11 - Assets and Liabilities Classified as Discontinued Operations (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 12 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 12 - Long-Term Debt Future Principal Payments (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 13 - Supplemental Cash Flow Information (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 idxg-20160331_cal.xml EXHIBIT 101.CAL EX-101.DEF 9 idxg-20160331_def.xml EXHIBIT 101.DEF EX-101.LAB 10 idxg-20160331_lab.xml EXHIBIT 101.LAB Document And Entity Information Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Tabular disclosure of the amounts from discontinued operations that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized. Research and development Goodwill and Intangible Assets, Policy [Policy Text Block] Schedule of Components of Loss from Discontinued Operations [Table Text Block] Tabular disclosure of the components of the loss from the entity's discontinued operations. Note To Financial Statement Details Textual statementsignificantaccountingpoliciespolicies Operating expenses: statementnote2liquidityandmanagementsplanstables us-gaap_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate Business Combination, Indemnification Assets, Amount as of Acquisition Date statementnote3summaryofsignificantaccountingpoliciestables statementnote4otherintangibleassetstables statementnote5fairvaluemeasurementstables Letters of credit Letters of credit that the company has extended to customers. statementnote6commitmentsandcontingenciestables Amendment Flag us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements statementnote7accruedexpensesandlongtermliabilitiestables us-gaap_TreasuryStockValue Treasury stock, at cost (542,543 and 1,042,543 shares, respectively) statementnote8stockbasedcompensationtables statementnote9incometaxestables statementnote11discontinuedoperationstables statementnote12longtermdebttables statementnote13supplementalcashflowinformationtables us-gaap_AllowanceForDoubtfulAccountsReceivable Allowance for Doubtful Accounts Receivable statementnote2contractualobligationsdueinthenext12monthsdetails statementnote3othercurrentassetsdetails us-gaap_OtherNoncashIncomeExpense Other (gains), losses and expenses, net statementnote3stockawardsexcludedfromthecomputationoftheeffectofdilutivesecuritiesdetails Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] statementnote3reconciliationofthenumberofsharesusedinbasicanddilutedearningspersharedetails Document Fiscal Year Focus statementnote4futureestimatedamortizationexpensedetails statementnote4identifiableintangibleassetscarryingvaluedetails Document Fiscal Period Focus us-gaap_ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt CLIA Diagnostic Lab [Member] Represents CLIA Diagnostic Lab. statementnote6severanceactivitydetails statementnote5financialinstrumentsdetails New Accounting Pronouncements and Changes in Accounting Principles [Text Block] statementnote7oherlongtermliabilitiesdetails Diagnostic Test, Biobank [Member] Represents the diagnostic tests for Biobank. Document Period End Date statementnote7accruedexpensesdetails Provision for bad debt statementnote9incometaxesdetails us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2018 Investments, fair value disclosure statementnote8weightedaverageassumptionsdetails us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2017 Other changes in assets and liabilities: statementnote11assetsandliabilitiesclassifiedasdiscontinuedoperationsdetails Current Fiscal Year End Date Cash and cash equivalents, fair value disclosure Sales and marketing statementnote11resultsincludedinlossfromdiscontinuedoperationsnetoftaxdetails statementnote13supplementalcashflowinformationdetails statementnote12longtermdebtfutureprincipalpaymentsdetails Notes To Financial Statements [Abstract] us-gaap_AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other Notes To Financial Statements Effective income tax rate Unrealized holding gain on available-for-sale securities, net Entity Current Reporting Status Entity Voluntary Filers Entity Filer Category Document Type us-gaap_NotesIssued1 Notes Issued Common Stock, Shares, Outstanding (in shares) Dividend yield us-gaap_AccountsReceivableNet Accounts Receivable, Net Cash Flows From Financing Activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities us-gaap_StockholdersEquity Total stockholders' equity Entity Well-known Seasoned Issuer us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss from continuing operations before tax us-gaap_InterestExpenseDebt Interest expense Interest Expense, Debt Cash and Cash Equivalents [Domain] Comprehensive loss Cash [Member] us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Revenue, net Statement of Financial Position [Abstract] Money Market Funds [Member] US Treasury Securities [Member] (Loss) income from discontinued operations, net of tax Preferred Stock, Shares Outstanding (in shares) Cash and Cash Equivalents [Axis] Reported Value Measurement [Member] Acquisition related amortization expense Amortization of Intangible Assets Operating Activities [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] us-gaap_LongTermDebt Long-term Debt us-gaap_IncreaseDecreaseInOtherCurrentAssets Increase in other current assets Discontinued Operations [Member] Continuing Operations [Member] Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Decrease in other long-term assets Operating Activities [Domain] us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent Property and equipment, net Disposal Group Name [Axis] Disposal Group Name [Domain] Long-term assets from discontinued operations us-gaap_TableTextBlock Notes Tables Statement [Table] us-gaap_DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount us-gaap_IncreaseDecreaseInUnbilledReceivables Decrease in unbilled receivable us-gaap_SeveranceCosts1 Severance Costs Accruals us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Income Statement [Abstract] Other Accrued Expenses [Member] Primary balance sheet location. us-gaap_IncreaseDecreaseInAccountsReceivable Decrease (increase) in accounts receivable Statement of Cash Flows [Abstract] Long-term Debt, Type [Domain] Long-term Debt, Type [Axis] us-gaap_DeferredRentCreditNoncurrent Rent payable Basic and diluted loss per share of common stock: From discontinued operations (in dollars per share) Basic weighted average number of common shares (in shares) From continuing operations (in dollars per share) Potential dilutive effect of stock-based awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Diluted weighted average number of common shares (in shares) Interest accretion Realignment accrual accretion Uncertain tax positions us-gaap_EarningsPerShareBasicAndDiluted Net loss per basic and diluted share of common stock (in dollars per share) us-gaap_RepaymentsOfLongTermDebt Repayments of Long-term Debt General and administrative us-gaap_OperatingExpenses Total operating expenses Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 2 [Member] Diagnostic Test, Barrett's RedPath [Member] Represents the diagnostic test Barrett's RedPath. RedPath [Member] Represents RedPath. Long-term debt, net of debt discount Diagnostic Test, Pancreas [Member] Represents the business segment that generates sales from the pancreas diagnostics product line. Interpace Diagnostics, LLC [Member] Reporting entity's wholly-owned subsidiary. us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities Other, liabilities Diagnostic Test, Thyroid [Member] Represents the segment that generates net sales from the thyroid diagnostics product line. Accumulated deficit Accumulated other comprehensive income us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Unearned contract revenue Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] us-gaap_SalesRevenueNet Revenue, net Schedule of Accrued Liabilities [Table Text Block] Fair Value, Inputs, Level 1 [Member] Accounts payable Other Noncurrent Liabilities [Member] us-gaap_IncreaseDecreaseInAccruedSalaries (Decrease) increase in accrued salaries and bonus Contractual Obligations, Due Other receivables Asuragen [Member] Represents Asuragen. Entity Registrant Name Entity Central Index Key Decrease in accounts payable Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Contingent consideration, deferred payments Entity Common Stock, Shares Outstanding (in shares) us-gaap_LettersOfCreditOutstandingAmount Letters of Credit Outstanding, Amount us-gaap_RestructuringReserve Balance as of December 31, 2015 Balance as of March 31, 2016 us-gaap_RegulatoryLiabilities Regulatory Liabilities Other Liabilities Disclosure [Text Block] Asuragen and Redpath [Member] Represents Asuragen and Redpath. idxg_BusinessCombinationContingentCashConsiderationRevenueBasedPayments Business Combination, Contingent Cash Consideration, Revenue Based Payments Represents contingent cash consideration related to revenue based payments. (Decrease) increase in long-term liabilities idxg_BusinessCombinationContingentCashConsiderationDeferredPayments Business Combination, Contingent Cash Consideration, Deferred Payments Represents contingent cash consideration for deferred payments. DOJ settlement (indemnified by RedPath) Contractual Obligations, Due in 3 to 6 Months Amount of contractual obligation due in four to six months. Accounts receivable, net Segment Reporting Disclosure [Text Block] Contractual Obligations, Due in 0 to 3 Months Amount of contractual obligation due in zero to three months. Cash and cash equivalents Cash and cash equivalents – beginning Cash and cash equivalents – ending Cash and Cash Equivalents, at Carrying Value Trading Symbol DOJ Settlement [Member] Contractual obligation to pay the Department of Justice as agreed upon in the settlement agreement. Other Liabilities Noncurrent Former Owners of RedPath [Member] Represents former owners of RedPath that has indemnified assets. us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Contingent consideration us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear 2016 Other long-term liabilities (Decrease) increase in unearned contract revenue Contractual Obligations, Due in 6 to 12 Months Amount of contractual obligation due in seven to twelve months us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Gain on sale of discontinued operations idxg_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDateNoncurrent Business Combination, Indemnification Assets, Amount as of Acquisition Date, Noncurrent The amount of indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination that are noncurrent. us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued Stock Issued During Period, Value, Treasury Stock Reissued Balance Sheet Location [Axis] Unclaimed property Represents unclaimed property. Decrease in accrued liabilities Balance Sheet Location [Domain] idxg_DebtInstrumentOneTimePaymentPrincipal Debt Instrument, One Time Payment, Principal Amount of the one time payment applied to principal. idxg_BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDateCurrent Business Combination, Indemnification Assets, Amount as of Acquisition Date, Current The amount of indemnification assets (amounts to be reimbursed if and when certain assumed liabilities are paid) recognized at the acquisition date of a business combination that are current. Investment Type [Axis] Investments [Domain] us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax (Loss) income from discontinued operations, before tax Income tax expense Current assets: Equity Component [Domain] Equity Components [Axis] Commercial Services [Member] Disposal group. us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net decrease in cash and cash equivalents us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Schedule of Weighted Average Number of Shares [Table Text Block] Provision (benefit) for income tax Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Class of Stock [Axis] us-gaap_EmployeeRelatedLiabilitiesCurrent Accrued salary and bonus Commitments and Contingencies Disclosure [Text Block] Short-term investments us-gaap_AccountsPayableCurrent Accounts payable Other accrued expenses DOJ settlement Reclassification, Policy [Policy Text Block] Common Stock, Par or Stated Value Per Share (in dollars per share) Common Stock, Par or Stated Value Per Share All others New Accounting Pronouncements, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Preferred Stock, Shares Issued (in shares) Schedule of Other Assets [Table Text Block] Schedule of Other Assets and Other Liabilities [Table Text Block] Schedule of Debt [Table Text Block] Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding Preferred Stock, Par or Stated Value Per Share (in dollars per share) Preferred Stock, Shares Authorized (in shares) us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense Cost of revenue (excluding amortization of $970 and $870, repectively) us-gaap_OperatingIncomeLoss Operating loss Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Self insurance accruals us-gaap_GrossProfit Gross profit us-gaap_LiabilitiesCurrent Total current liabilities Liabilities, Current us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Contingent consideration Treasury Stock, Shares (in shares) us-gaap_PaymentsForRepurchaseOfCommonStock Cash paid for repurchase of restricted shares Current liabilities from discontinued operations Substantial Doubt about Going Concern [Text Block] Common Stock, Shares, Issued (in shares) Indemnification liability Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively Common Stock, Shares Authorized (in shares) Accounting Policies [Abstract] Subsequent Event Type [Domain] Rent payable Subsequent Event Type [Axis] Statement [Line Items] Other income (expense), net Subsequent Event [Member] us-gaap_PolicyTextBlockAbstract Accounting Policies Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Trade and Other Accounts Receivable, Policy [Policy Text Block] Cash Flows From Investing Activities us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash Flows From Operating Activities Scenario, Unspecified [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Title of Individual [Axis] Fair Value Disclosures [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash (used in) provided by operating activities of discontinued operations Relationship to Entity [Domain] Current portion of long-term debt, net of debt discount Net cash provided by (used in) investing activities of discontinued operations Scenario [Axis] Director [Member] Fair Value, by Balance Sheet Grouping [Table Text Block] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Property and equipment, net us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Other intangible assets, net us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Estimate of Fair Value Measurement [Member] Other long-term assets Measurement Basis [Axis] Fair Value Measurement [Domain] Weighted average number of common shares and common share equivalents outstanding: Income Tax Disclosure [Text Block] us-gaap_PaymentsForFees Payments for Other Fees Indemnification assets Cash paid for interest Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_LitigationSettlementAmount Litigation Settlement, Amount Basis of Presentation and Significant Accounting Policies [Text Block] Restructuring and Related Costs [Table Text Block] Taxes payable Type of Restructuring [Domain] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Finite-lived intangible asset, useful life Restructuring Type [Axis] Cash Flow, Supplemental Disclosures [Text Block] Accrued professional fees Equity Award [Domain] Employee Severance [Member] Award Type [Axis] Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Depreciation and amortization Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Other Net loss Net loss Net Income (Loss) Attributable to Parent us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2016 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2017 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2018 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2019 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2020 Total assets RedPath Integrated Pathology, Inc [Member] Acquired entity. us-gaap_IncomeLossFromContinuingOperations Loss from continuing operations us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 6) Total liabilities Amortization us-gaap_Assets Total assets Performance Shares [Member] Prepaid expenses Facilities realignment accrual Current liabilities: Stock Appreciation Rights (SARs) [Member] Restricted Stock Units (RSUs) [Member] us-gaap_OtherAssetsCurrent Other current assets Antidilutive Securities, Name [Domain] Stock-based compensation Employee Stock Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Unbilled receivable, net Antidilutive Securities [Axis] RSU's and Restricted Stock [Member] Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met and stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Goodwill and Intangible Assets Disclosure [Text Block] Long-term Debt [Text Block] Loans Payable [Member] us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets Other Notes Payable, Other Payables [Member] us-gaap_LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value Additional paid-in capital Counterparty Name [Domain] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Counterparty Name [Axis] Current assets from discontinued operations Earnings Per Share, Policy [Policy Text Block] us-gaap_PaymentsForRestructuring Payments us-gaap_OtherAssets Other Discontinued Operations, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Risk-free interest rate us-gaap_NumberOfReportableSegments Number of Reportable Segments Other Discontinued Operations [Member] Represents all other disposal groups. us-gaap_AssetsCurrent Total current assets Expected volatility Stockholders’ equity: Accrued salary and bonus Represents Disposal Group, Including Discontinued Operation, Accrued Salary and Bonus. us-gaap_ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets Expected life (years) Finite-Lived Intangible Assets, Net us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Business Combination, Consideration Transferred, Liabilities Incurred us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization EX-101.PRE 11 idxg-20160331_pre.xml EXHIBIT 101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 06, 2016
Entity Registrant Name Interpace Diagnostics Group, Inc.  
Entity Central Index Key 0001054102  
Trading Symbol idxg  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   18,162,671
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 4,340 $ 8,310
Short-term investments 106
Accounts Receivable, Net $ 2,780 2,806
Other current assets 3,024 2,569
Current assets from discontinued operations 1,530 5,374
Total current assets 11,674 19,165
Property and equipment, net 1,330 1,460
Other intangible assets, net 42,522 43,492
Other long-term assets 1,066 3,255
Long-term assets from discontinued operations 183 340
Total assets 56,775 67,712
Current liabilities:    
Accounts payable 1,245 1,560
Accrued salary and bonus 2,869 2,424
Other accrued expenses 6,655 5,961
Current portion of long-term debt, net of debt discount 2,463 1,164
Current liabilities from discontinued operations 6,514 12,264
Total current liabilities 19,746 23,373
Contingent consideration 17,890 17,890
Long-term debt, net of debt discount 6,137 7,233
Other long-term liabilities 4,696 6,178
Total liabilities $ 48,469 $ 54,674
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $.01 par value; 100,000,000 shares authorized; 18,705,214 shares issued; 18,162,671 and 17,662,671 shares outstanding, respectively $ 187 $ 187
Additional paid-in capital 125,800 132,522
Accumulated deficit $ (116,038) (111,252)
Accumulated other comprehensive income 13
Treasury stock, at cost (542,543 and 1,042,543 shares, respectively) $ (1,643) (8,432)
Total stockholders' equity 8,306 13,038
Total liabilities and stockholders' equity $ 56,775 $ 67,712
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01 $ 0.01
Preferred Stock, Shares Authorized (in shares) 5,000,000 5,000,000
Preferred Stock, Shares Issued (in shares) 0 0
Preferred Stock, Shares Outstanding (in shares) 0 0
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01 $ 0.01
Common Stock, Shares Authorized (in shares) 100,000,000 100,000,000
Common Stock, Shares, Issued (in shares) 18,705,214 18,705,214
Common Stock, Shares, Outstanding (in shares) 18,162,671 17,662,671
Treasury Stock, Shares (in shares) 542,543 1,042,543
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue, net $ 3,035 $ 2,117
Cost of revenue (excluding amortization of $970 and $870, repectively) 1,179 1,574
Gross profit 1,856 543
Operating expenses:    
Sales and marketing 1,547 2,226
Research and development 323 232
General and administrative 2,816 3,339
Acquisition related amortization expense 970 870
Total operating expenses 5,656 6,667
Operating loss (3,800) (6,124)
Interest expense (203) (848)
Other income (expense), net 6 (86)
Loss from continuing operations before tax (3,997) (7,058)
Provision (benefit) for income tax 9 (73)
Loss from continuing operations (4,006) (6,985)
(Loss) income from discontinued operations, net of tax (780) 3,117
Net loss $ (4,786) $ (3,868)
Unrealized holding gain on available-for-sale securities, net
Comprehensive loss $ (4,786) $ (3,868)
Basic and diluted loss per share of common stock:    
From continuing operations (in dollars per share) $ (0.23) $ (0.46)
From discontinued operations (in dollars per share) (0.04) 0.21
Net loss per basic and diluted share of common stock (in dollars per share) $ (0.27) $ (0.26)
Weighted average number of common shares and common share equivalents outstanding:    
Basic weighted average number of common shares (in shares) 17,762 15,037
Diluted (in shares) 17,762 15,037
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Amortization $ 970 $ 870
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash Flows From Operating Activities    
Net loss $ (4,786) $ (3,868)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,257 1,195
Realignment accrual accretion 16 35
Interest accretion 203 261
Provision for bad debt $ 89 96
Gain on sale of discontinued operations (285)
Stock-based compensation $ 67 $ 396
Other (gains), losses and expenses, net (13)
Other changes in assets and liabilities:    
Decrease (increase) in accounts receivable 4,270 $ (5,229)
Decrease in unbilled receivable 16 420
Increase in other current assets (460) (438)
Decrease in other long-term assets 689 2,156
Decrease in accounts payable (1,887) (1,274)
(Decrease) increase in unearned contract revenue (11) 4,144
(Decrease) increase in accrued salaries and bonus (372) 1,040
Decrease in accrued liabilities (2,566) (4,602)
(Decrease) increase in long-term liabilities (482) 336
Net cash used in operating activities $ (3,970) (5,617)
Cash Flows From Investing Activities    
Purchase of property and equipment (464)
Net cash used in investing activities (464)
Cash Flows From Financing Activities    
Cash paid for repurchase of restricted shares (26)
Net cash used in financing activities (26)
Net decrease in cash and cash equivalents $ (3,970) (6,107)
Cash and cash equivalents – beginning 8,310 23,111
Cash and cash equivalents – ending $ 4,340 17,004
Cash paid for interest $ 818
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 1 - Basis of Presentation
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.
BASIS OF PRESENTATION
 
The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc.
(the Company or Interpace), and its wholly-owned subsidiaries, Interpace Diagnostics Corporation and Interpace Diagnostics, LLC,
and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission (SEC) on March 30, 2016.  The condensed interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  The condensed interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.  All significant intercompany balances and transactions have been eliminated in consolidation.  Discontinued operations include the Company's wholly-owned subsidiaries: Group DCA, LLC, or Group DCA; InServe Support Solutions (Pharmakon); and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services business unit. All significant intercompany balances and transactions have been eliminated in consolidation.
Operating results for the three-month period ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 2 - Liquidity and Management's Plans
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Substantial Doubt about Going Concern [Text Block]
2.
LIQUIDITY AND MANAGEMENT'S PLANS
 
For the three months ended March 31, 2016, the Company incurred a net loss of $4.8 million and cash used in operating activities was $4.0 million.  The Company did not raise any capital or incur any additional debt during the first quarter of 2016. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to ramping up its commercial operations, further developing its products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations. The accompanying condensed, consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2016, the Company had cash and cash equivalents of $4.3 million, net accounts receivable of $2.8 million and current liabilities of $19.7 million.
 
As a result of the sale of substantially all of its Commercial Services Organization (CSO) business in December 2015, which generated net cash proceeds of $26.8 million (of which $21.6 million was used to repay long-term debt and fees), the Company focused its resources and strategic initiatives on the molecular diagnostics business. As with many companies in a similar stage, sufficient capital is required before achieving profitability. Accordingly, the Company will require additional capital in 2016 and beyond and in order to obtain such capital and fund its operations, may be required to restructure all or a portion of its obligations related to the sale of its CSO business. There is, however, no guarantee that additional capital will or can be raised or that adequate restructuring will be accomplished that is sufficient to fund the Company's operations in 2016 and beyond or that the terms of such additional capital, if available, will be acceptable to the Company. Accordingly, the Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances and alternatives, business development and other sources. Additionally, the Company intends to help meet its capital needs by driving revenue growth of our commercial molecular diagnostic tests, closely managing cash and further streamlining operations. If, however, the Company is unsuccessful in executing its plans for the business to continue operations, when needed, including the restructuring of its debt and other liabilities, then it may be forced to seek protection under the U.S. Bankruptcy Code, or be forced into liquidation or substantially alter or restructure its business operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
 
 
A summary of the Company’s significant contractual obligations as of March 31, 2016 over the next 12 months are as follows:
 
   
Total
   
0 to 3
months
   
3 to 6
months
   
6 to 12
months
 
Note due Redpath Equityholders
  $ 2,668     $ -     $ -     $ 2,668  
Severance obligations
    3,675       2,774       901       -  
Department of Justice ("DOJ") settlement
    750       -       85       665 *
Asuragen Deferred Purchase Price
    500       300       200       -  
Total obligations
  $ 7,593     $ 3,074     $ 1,186     $ 3,333  
 
* Estimated liability based on our current revenue expectation.
 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 3 - Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Basis of Presentation and Significant Accounting Policies [Text Block]
3.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Accounting Estimates
 
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
 
Reclassifications
 
The Commercial Services business in the period ended March 31, 2015 has been reclassified to discontinued operations to conform to the current period presentation.
 
Receivables and Allowance for Doubtful Accounts
 
The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.
 
The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $0.9 million allowance for doubtful accounts as of March 31, 2016.
 
 
Other Current Assets
 
Other current assets consisted of the following as of March 31, 2016 and December 31, 2015:
 
   
March 31, 2016
   
December 31, 2015
 
Indemnification assets
  $ 1,375     $ 875  
Letters of credit
    344       360  
Other receivables
    960       1,048  
Prepaid expenses
    243       180  
Other
    102       106  
    $ 3,024     $ 2,569  
 
 
Other Intangible Assets
 
The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.
 
Discontinued Operations
 
The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11,
Discontinued Operations
for further information.
 
Basic and Diluted Net Loss per Share
 
A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2016 and 2015 is as follows:
 
   
Three Months Ended
 
   
March 31,
 
   
2016
   
2015
 
Basic weighted average number 
of common shares
    17,762       15,037  
Potential dilutive effect of stock-based awards
    -       -  
Diluted weighted average number
of common shares
    17,762       15,037  
 
The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
 
 
   
March 31,
 
   
2016
   
2015
 
Options
    -       25  
Stock-settled stock appreciation rights (SARs)
    1,027       1,066  
Restricted stock and restricted stock units (RSUs)
    1,317       1,632  
Performance contingent SARs
    -       188  
      2,344       2,911  
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 4 - Other Intangible Assets
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
4.
OTHER INTANGIBLE ASSETS
 
 
The net carrying value of the identifiable intangible assets as of March 31, 2016 is as follows: 
 
           
As of March 31, 2016
 
   
Life
   
Carrying
 
   
(Years)
   
Amount
 
Diagnostic assets:
 
 
 
 
 
 
 
 
Asuragen acquisition:
               
Thyroid
    9     $ 8,519  
Pancreas
    7       2,882  
Biobank
    4       1,575  
RedPath acquisition:
               
Pancreas test
    7       16,141  
Barrett's test
    9       18,351  
Total
          $ 47,468  
Diagnostic lab:
 
 
 
 
 
 
 
 
CLIA Lab
    2.3     $ 609  
                 
Accumulated Amortization
          $ (5,555 )
                 
Net Carrying Value
          $ 42,522  
 
Amortization expense was $1.0 million and $0.9 million for the three month periods ended March 31, 2016 and 2015, respectively. Amortization of the Company's diagnostic assets begin upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:
 
2016
   
2017
   
2018
   
2019
   
2020
 
$ 4,889     $ 6,097     $ 5,949     $ 5,703     $ 5,703  
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 5 - Fair Value Measurements
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
5.
FAIR VALUE MEASUREMENTS
 
The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods, including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:
 
 
Level 1:
Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
 
 
Level 2:
Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
 
 
Level 3:
Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.
 
In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.
 
   
As of March 31, 2016
   
Fair Value Measurements
 
   
Carrying
   
Fair
   
As of March 31, 2016
 
   
Amount
   
Value
   
Level 1
   
Level 2
     
Level 3
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
                                         
Cash
  $ 3,564     $ 3,564     $ 3,564     $ -  
 
  $ -  
Money market funds
    776       776       776       -         -  
    $ 4,340     $ 4,340     $ 4,340     $ -       $ -  
Marketable securities:
                                         
U.S. Treasury securities
  $ 553     $ 553     $ 553     $ -       $ -  
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration:
                                         
Asuragen
  $ 4,628     $ 4,628     $ -     $ -       $ 4,628  
RedPath
    13,921       13,921       -       -         13,921  
    $ 18,549     $ 18,549     $ -     $ -       $ 18,549  
 
 
The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of March 31, 2016, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3).
 
In connection with the acquisition of assets from Asuragen and the acquisition of RedPath, the Company has recorded $4.6 million and $13.9 million of contingent cash consideration related to deferred payments and revenue based payments, respectively. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.  There was no change in the fair value of the contingent consideration during the period ended March 31, 2016.
 
The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.  There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.
 
Certain of the Company's non-financial assets, such as other intangible assets, are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 6 - Commitments and Contingencies
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
6
.
COMMITMENTS AND CONTINGENCIES
 
Letters of Credit
 
As of March 31, 2016, the Company had $0.5 million in letters of credit outstanding as required by its existing insurance policies and its facility leases. These letters of credit are collateralized by certain investments.
 
Contingency
 
 
In connection with the acquisition of RedPath on October 31, 2014, the Company and its wholly-owned subsidiary, Interpace Diagnostics, LLC (Interpace LLC) entered into a Contingent Consideration Agreement with RedPath Equityholder Representative, LLC (the Equityholder Representative). Pursuant to the Contingent Consideration Agreement, the Company agreed to issue to the equityholders of RedPath 500,000 shares of the Company’s common stock, par value $0.01 (Common Stock), upon acceptance for publication of a specified article related to PathFinderTG® for the management of Barrett’s esophagus. The pending issuance of Common Stock was recorded as Additional paid-in capital in the Company's consolidated balance sheet as of December 31, 2014. On April 13, 2015, this milestone was reached upon acceptance for publication of new data supporting the use of BarreGen™ for predicting risk of progression from Barrett’s esophagus to esophageal cancer. On June 16, 2015, the 500,000 shares were issued from Treasury stock decreasing the balance in treasury stock by approximately $6.1 million, with a corresponding decrease in Additional paid-in capital of $6.1 million. In March 2016, 500,000 additional shares of Common Stock were issued from Treasury stock, as a result of the acceleration of the Common Stock Milestone, as defined in the Contingent Consideration Agreement, resulting from the change of control in connection with the sale of its Commercial Services (CSO) business in December 2015, decreasing the balance in Treasury stock by approximately $6.8 million, with a corresponding decrease in Additional paid-in capital of $6.8 million.
 
Litigation
 
Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. As part of the closeout of its CSO operations, the Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.
 
The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of March 31, 2016, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.
 
In connection with the October 31, 2014 acquisition of RedPath, the Company assumed a liability for a January 2013 settlement agreement (the Settlement Agreement) entered into by the former owners of RedPath with the Department of Justice (“DOJ”). Under the terms of the Settlement Agreement, the Company is obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million.
 
 
Payments are due March 31st following the calendar year that the revenue milestones are achieved. The Company has been indemnified by the former owners of RedPath for up to $2.5 million of the obligation, with the first $0.5 million payable by the Company. At March 31, 2016, the Company has recorded an indemnification asset of $1.5 million of which $0.5 is included in
other current assets
and $1.0 million is included in
other non-current assets
. At March 31, 2016, the Company has $1.8 million recorded as its best estimate of the amount that remains to be paid under the Settlement Agreement based on its estimate of future revenues, of which $0.8 million is included in
other accrued expenses
and $1.0 million is included in
other long-term liabilities
. In May 2016, the Company negotiated a payment plan with the DOJ to pay the $250,000 currently due based on its 2015 revenues in three relatively equal installments in August 2016, October 2016 and February 2017.
 
Prolias Technologies, Inc. v. PDI, Inc.
 
On April 8, 2015, Prolias Technologies, Inc., or Prolias, filed a complaint (the Complaint) against the Company with the Superior Court of New Jersey (Morris County) in a matter entitled Prolias Technologies, Inc. v. PDI, Inc. (Docket No. MRS-L-899-15).  In the Complaint, Prolias alleges that it and the Company entered into an August 19, 2013 Collaboration Agreement and a First Amendment thereto, collectively the Agreement, whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as "Thymira."  Thymira is a minimally invasive diagnostic test that is being developed to detect thyroid cancer.
 
Prolias alleges in the Complaint that the Company wrongfully terminated the Agreement, breached obligations owed to it under the Agreement and committed torts by (i) failing to effectively and timely validate Thymira, (ii) purchasing a competitor of Prolias and working to commercialize the competitive product at the expense of Thymira, and (iii) interfering with a license agreement that Prolias had with Cornell University related to a license for Thymira. Prolias asserts claims against the Company for breach of contract, breach of the covenant of good faith and fair dealing, intentional interference with contract and breach of fiduciary duty and seeks to recover unspecified compensatory damages, punitive damages, interest and costs of suit.
 
On June 3, 2015, the Company filed an Answer and Counterclaim in response to the Complaint. In the Answer, the Company denied liability for the claims being asserted in the Complaint. In the Counterclaim, the Company asserted claims against Prolias for breaches of the Agreement and for a declaratory judgment. The Company seeks damages from Prolias in excess of $500,000 plus interest and attorney’s fees and costs, together with a declaration compelling Prolias to execute and deliver to the Company a promissory note in the amount of One Million Five Hundred Thousand Dollars ($1,500,000.00) to evidence Prolias’ obligation to repay the Company for amounts that were advanced.
 
After the Answer and Counterclaim were filed, the Company and Prolias exchanged paper discovery.  In early December 2015, Prolias replaced its counsel with new counsel.  Thereafter, on December 18, 2015, Prolias filed an Order to Show Cause and Temporary Restraining Order (TRO) that sought to (a) enjoin the Company from selling the assets that comprise its CSO business to Publicist Healthcare Communications Group and (b) disqualify the Company's counsel from representing it in the litigation.
 
On December 21, 2015, the Court held a hearing on Prolias's application to temporarily enjoin the sale of the CSO business. Following the hearing the Court denied Prolias's application for a TRO and set a hearing date on the motions to disqualify counsel and to obtain an injunction.
 
On February 4, 2016, the Court heard argument on Prolias's motions to disqualify the Company’s counsel and to obtain an injunction with respect to the CSO sale. Following the hearing, the Court entered orders denying the motion to disqualify and denying the motion for an injunction.
 
On February 24, 2016, Prolias filed a motion before the New Jersey Appellate Division to appeal on an interlocutory basis the order denying the motion to disqualify.  The Company filed its opposition to the motion on March 7, 2016.  It is not known when the Appellate Division will rule on the motion for leave to take an interlocutory appeal, and further it is not known whether, if Prolias is successful in obtaining leave to appeal, what would be the result of the appeal. Progress on the case has been stayed pending resolution of this issue. In the interim, counsel for Prolias has filed for permission to withdraw as counsel, citing nonpayment of its bills. That motion also remains pending.
 
The Company denies that it is liable to Prolias for any of the claims asserted in the Complaint and it intends to (a) vigorously defend itself against those claims, (b) pursue all claims asserted in the Counterclaim and (c) vigorously oppose the motion for leave to appeal.
 
Severance
 
 
In 2015, in connection with the sale of substantially all of the CSO business and the implementation of a broad-based program to maximize efficiencies and cut costs, the Company reduced headcount and incurred severance obligations to terminated employees that amounted to $3.7 million.
 
During the three month period ended March 31, 2016 the Company recorded additional severance obligations as it discontinued the remainder of its CSO business and recorded obligations of $1.1 million, $0.5 million of which was recorded in continuing operations within general and administrative expenses in the Condensed Consolidated Statement of Comprehensive Loss. A rollforward of the severance activity is as follows:
 
   
Continuing
   
Discontinued
         
   
Operations
   
Operations
   
Total
 
                         
Balance as of December 31, 2015
  $ 2,011     $ 1,074     $ 3,085  
Accruals
    459       659       1,118  
Payments
    (140 )     (388 )     (528 )
Balance as of March 31, 2016
  $ 2,330     $ 1,345     $ 3,675  
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 7 - Accrued Expenses and Long-term Liabilities
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]
7.
ACCRUED EXPENSES AND LONG-TERM LIABILITIES
 
Other accrued expenses consisted of the following as of March 31, 2016 and December 31, 2015:
 
   
March 31, 2016
   
December 31, 2015
 
Facilities realignment accrual
  $ -     $ 43  
Self insurance accruals
    66       137  
Indemnification liability
    875       875  
Contingent consideration
    659       659  
Rent payable
    104       127  
DOJ settlement
    750       250  
Accrued professional fees
    1,084       775  
Taxes payable
    622       591  
Unclaimed property
    544       546  
All others
    1,951       1,958  
    $ 6,655     $ 5,961  
 
 
 
Long-term liabilities consisted of the following as of March 31, 2016 and December 31, 2015:
 
 
   
March 31, 2016
   
December 31, 2015
 
Rent payable
  $ 27     $ 52  
Uncertain tax positions
    3,468       3,425  
DOJ settlement (indemnified by RedPath)
    1,000       2,500  
Other
    201       201  
    $ 4,696     $ 6,178  
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 8 - Stock-based Compensation
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
8
.
STOCK-BASED COMPENSATION
 
Stock Incentive Plan
 
In 2015, the Board and stockholders approved the Company’s Amended and Restated 2004 Stock Award and Incentive Plan, or the Amended and Restated Plan. The Amended and Restated Plan amends the Company’s pre-existing Amended and Restated 2004 Stock Award and Incentive Plan which had replaced the 1998 Stock Option Plan, or the 1998 Plan, and the 2000 Omnibus Incentive Compensation Plan, or the 2000 Plan.  The Amended and Restated Plan authorized an additional 2,450,000 shares for new awards and combined the remaining shares available under the original Amended and Restated Plan.  Eligible participants under the Amended and Restated Plan include officers and other employees of the Company, members of the Board and outside consultants, as specified under the Amended and Restated Plan and designated by the Compensation and Management Development Committee of the Board, or the Compensation Committee.  Unless earlier terminated by action of the Board, the Amended and Restated Plan will remain in effect until such time as no stock remains available for issuance under the Amended and Restated Plan and the Company has no further rights or obligations under the Amended and Restated Plan with respect to outstanding awards thereunder. 
 
SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant.  The restricted shares and restricted stock units (RSU’s) granted to employees historically have had a three year cliff vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.
 
In February 2016, certain employees and members of the Company’s Board of Directors were granted approximately 1.3 million RSU’s at a weighted average grant price of $0.25. These shares vest one-third each year on the anniversary of the date of grant.
 
The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the three month periods ended March 31, 2016 and March 31, 2015: 
 
   
Three Months Ending
 
   
March 31,
 
   
2016
   
2015
 
Risk-free interest rate
    -       0.97%  
Expected life (years)
    -       3.5  
Expected volatility
    -       52.03%  
Dividend yield
    -       -  
 
The Company recognized approximately $0.1 million and $0.2 million of stock-based compensation expense during each of the three month periods ended March 31, 2016 and 2015, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 9 - Income Taxes
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
9.
INCOME TAXES
 
Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.  As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.  The following table summarizes income tax (benefit) expense on loss from continuing operations and the effective tax rate for the three- month periods ended March 31, 2016 and 2015: 
 
 
 
   
Three Months Ended
 
   
March 31,
 
   
2016
   
2015
 
Provision (benefit) for income tax
  $ 9     $ (73 )
Effective income tax rate
    0.2 %     1.0 %
 
Income tax expense for the quarter ended March 31, 2016 was due to minimum state and local taxes. Income tax benefit for the quarter ended March 31, 2015 was primarily due to net operating losses, partially offset by minimum state and local taxes.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 10 - Segment Information
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
10.
SEGMENT INFORMATION
 
Effective December 31, 2015, the Company has one reporting segment: the Company's molecular diagnostics business, after the divestiture of its Commercial Services business on December 22, 2015. The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.
 
The Company's molecular diagnostics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 11 - Discontinued Operations
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]
11.
DISCONTINUED OPERATIONS
 
The table below presents the significant components of Commercial Services, Group DCA's, Pharmakon's and TVG’s results included in Loss from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive loss for the years ended March 31, 2016 and 2015.
 
 
   
Three Months Ending March 31,
 
   
2016
   
2015
 
Revenue, net
  $ 1,644     $ 36,463  
                 
(Loss) income from discontinued operations, before tax
    (735 )*     3,118  
Income tax expense
    45       1  
(Loss) income from discontinued operations, net of tax
  $ (780 )   $ 3,117  
 
* Approximately $659,000 of the balance relates to severance relating to terminated employees.
 
The assets and liabilities classified as discontinued operations relate to Commercial Services, Group DCA, Pharmakon, and TVG. As of March 31, 2016 and December 31, 2015, these assets and liabilities are in the accompanying balance sheets as follows:
 
   
For the Three Months Ended
March 31, 2016
   
For the Year Ended
December 31, 2015
 
   
CSO
   
DCA/
TVG
   
Total
   
CSO
   
DCA/
TVG
   
Total
 
Accounts receivable, net
  735     -     735     3,296     -     3,296  
Unbilled receivable, net
    -       -       -       16       -       16  
Other
    795       -       795       2,062       -       2,062  
Current assets from discontinued operations
    1,530       -       1,530       5,374       -       5,374  
Property and equipment, net
    33       -       33       190       -       190  
Other
    -       150       150       -       150       150  
Long-term assets from discontinued operations
    33       150       183       190       150       340  
Total assets
  1,563     150     1,713     5,564     150     5,714  
                                                 
Accounts payable
  2,195     -     2,195     3,767     -     3,767  
Unearned contract revenue
    -       -       -       11       -       11  
Accrued salary and bonus
    2,219       -       2,219       3,036       -       3,036  
Other
    1,812       288       2,100       5,092       358       5,450  
Current liabilities from discontinued operations
    6,226       288       6,514       11,906       358       12,264  
Total liabilities
  6,226     $ 288     6,514     11,906     358     12,264  
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 12 - Long-term Debt
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Long-term Debt [Text Block]
12.
LONG-TERM DEBT
 
On October 31, 2014, the Company and Interpace LLC, entered into an agreement to acquire RedPath (the Transaction). In connection with the Transaction, the Company entered into a note with the Equityholder Representative, dated October 31, 2014 (as amended, the Note).
 
The Note is for $11.0 million, interest-free and payable in eight equal consecutive quarterly installments beginning October 1, 2016. In the second quarter of 2015, the final working capital adjustment was made, reducing the balance of the Note to approximately $10.7 million. In October 2015, in connection with the sale of substantially all of the CSO business in December 2015, the Note was amended to, among other things:
 
 
permit the Company to enter into a revolving loan facility,
 
permit the Company to sell the CSO business and to use the proceeds of the CSO sale to pay off the amounts due under the existing $20 million Credit Agreement and to continue to
make payments on the debt due under the Note in accordance with the terms of the Note
,
 
provide that, upon written request by the Equityholder Representative on April 30, 2016, the Company would make a one-time principal payment in the amount of $1,333,750 on July 1, 2016 rather than as originally due on July 1, 2018 (which such request the Company did not receive), and
 
provide that the 500,000 shares of the Company’s common stock to be issued upon the commercial launch of PancraGen® for the management of Barrett’s esophagus would be deemed earned by the former RedPath Equityholders as of the closing of the sale of the CSO business (see Note 6,
Commitments and Contingencies
).
 
 
The interest rate will be 5.0% in the event of a default under the Note. The obligations of the Company under the Note are guaranteed by the Company and its subsidiaries in favor of the Equityholder Representative. Pursuant to the guarantee, the Company and its subsidiaries also granted a security interest in substantially all of their assets, including intellectual property, to secure their obligations to the Equityholder Representative. Based on the Company's incremental borrowing rate under its Credit Agreement, the fair value of the Note at the date of issuance was $7.5 million. During the quarters ended March 31, 2016 and 2015, the Company accreted approximately $0.2 million into interest expense, respectively, for each period. As of March 31, 2016, the balance of the Note is approximately $8.6 million and the unamortized discount is $2.1 million.
 
Principal payments due related to the long-term debt over next three years are as follows:
 
 
   
2016
 
2017
 
2018
Note
  $ 1,334       $ 5,335       $ 4,001    
 
As discussed in Footnote 6, the Company currently has an indemnification asset and liability of $1.5 million ($0.5 million short-term and $1.0 million long-term) relating to the DOJ settlement with the former owners of RedPath that was recorded with the acquisition of RedPath. As the Company makes payments to the DOJ, it may reduce the balance owed on the note by the same amount.
  
In addition, the Company entered into the Credit Agreement with the Agent and the Lenders, as defined in the agreement, in connection with the Transaction in the aggregate principal amount of $20.0 million (the Loan). The maturity date of the loan was October 31, 2020. The Company received net proceeds of approximately $19.6 million following payment of certain fees and expenses in connection with the Credit Agreement.
 
Upon the sale of substantially all of the Commercial Services (CSO) business on December 22, 2015, the Company was obligated to use a portion of the net proceeds from the transaction to pay the balance of the outstanding Loan in the aggregate principal amount of $20.0 million, an exit fee and expenses of approximately $1.6 million. In connection with the termination of the Credit Agreement, the Guarantee and Collateral Agreement, dated October 31, 2014, by the Company and certain of its subsidiaries in favor of the Agent was also terminated on December 22, 2015.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 13 - Supplemental Cash Flow Information
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Cash Flow, Supplemental Disclosures [Text Block]
13.
S
UPPLEMENTAL CASH FLOW INFORMATION
 
The following table represents cash flows (used in) provided by the Company's discontinued operations for the three months ended March 31, 2016 and 2015:
 
   
For The Three Months Ended March 31
 
   
2016
   
2015
 
Net cash (used in) provided by operating activities of discontinued operations
  $ (2,171 )   $ 6,073  
                 
Net cash provided by (used in) investing activities of discontinued operations
  $ -     $ -  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 14 - Recent Accounting Pronouncements
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
14.
RECENT ACCOUNTING PRONOUNCEMENTS
 
 
In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance permits the use of either a retrospective or cumulative effect transition method. In July 2015, the FASB approved a one-year deferral of the effective date of the guidance to interim and annual periods beginning on or after December 15, 2017. Early adoption is permitted but not before the original effective date of December 15, 2016. The Company has not yet selected a transition method and is currently evaluating the impact of the amended guidance on the Company’s consolidated financial position, results of operations and related disclosures.
 
In August 2014, the FASB issued guidance on determining when and how to disclose going-concern uncertainties in financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its
consolidated financial position, results of operations and related disclosures.
 
In March 2016, the FASB issued guidance
which clarifies the implementation guidance on principal versus agent considerations in the revenue recognition standard issued in May 2014. The new standard clarifies how an entity should identify the unit of accounting (i.e. the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The effective date and transition requirements are the same as the effective date and transition requirements in the May 2014 revenue standard (Accounting Standards Codification 606). The Company is currently assessing the adoption methodology and the impact the adoption of these ASUs will have on its
consolidated financial position, results of operations and related disclosures.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]
Accounting Estimates
 
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
Reclassification, Policy [Policy Text Block]
Reclassifications
 
The Commercial Services business in the period ended March 31, 2015 has been reclassified to discontinued operations to conform to the current period presentation.
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Receivables and Allowance for Doubtful Accounts
 
The Company’s accounts receivable are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payor or hospital. The Company recognizes accounts receivable related to billings for Medicare, Medicare Advantage, and hospitals on an accrual basis, net of contractual adjustment, when collectability is reasonably assured. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to hospitals. The Company records an Allowance for Doubtful accounts for PancraGen® hospital roster billings based on the collection history of this payor. Since Medicare and Medicare Advantage have fixed reimbursement rates, there is no Allowance for Doubtful Accounts associated with these payors.
 
The Company provides services to commercial insurance carriers or governmental programs that do not have a contract in place for its proprietary tests which may or may not be covered by these entities existing reimbursement policies. In addition, the Company does not enter into direct agreements with patients that commit them to pay any portion of the cost of the tests in the event that their commercial insurance carrier or governmental program does not pay the Company for its services. In the absence of an agreement with the patient, or other clearly enforceable legal right to demand payment from commercial insurance carriers or governmental agencies, no accounts receivable is recognized. The Company does not record an Allowance for Doubtful Accounts for the commercial insurance or governmental programs since the revenue is recorded mainly on a cash basis. There was approximately a $0.9 million allowance for doubtful accounts as of March 31, 2016.
Goodwill and Intangible Assets, Policy [Policy Text Block]
Other Intangible Assets
 
The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill, if any. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the intangible assets.
Discontinued Operations, Policy [Policy Text Block]
Discontinued Operations
 
The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11,
Discontinued Operations
for further information.
Earnings Per Share, Policy [Policy Text Block]
Basic and Diluted Net Loss per Share
 
A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2016 and 2015 is as follows:
 
   
Three Months Ended
 
   
March 31,
 
   
2016
   
2015
 
Basic weighted average number 
of common shares
    17,762       15,037  
Potential dilutive effect of stock-based awards
    -       -  
Diluted weighted average number
of common shares
    17,762       15,037  
 
The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
 
 
   
March 31,
 
   
2016
   
2015
 
Options
    -       25  
Stock-settled stock appreciation rights (SARs)
    1,027       1,066  
Restricted stock and restricted stock units (RSUs)
    1,317       1,632  
Performance contingent SARs
    -       188  
      2,344       2,911  
New Accounting Pronouncements, Policy [Policy Text Block]
In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance permits the use of either a retrospective or cumulative effect transition method. In July 2015, the FASB approved a one-year deferral of the effective date of the guidance to interim and annual periods beginning on or after December 15, 2017. Early adoption is permitted but not before the original effective date of December 15, 2016. The Company has not yet selected a transition method and is currently evaluating the impact of the amended guidance on the Company’s consolidated financial position, results of operations and related disclosures.
 
In August 2014, the FASB issued guidance on determining when and how to disclose going-concern uncertainties in financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is evaluating the potential impact of the new guidance on its quarterly reporting process and its
consolidated financial position, results of operations and related disclosures.
 
In March 2016, the FASB issued guidance
which clarifies the implementation guidance on principal versus agent considerations in the revenue recognition standard issued in May 2014. The new standard clarifies how an entity should identify the unit of accounting (i.e. the specified good or service) for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The effective date and transition requirements are the same as the effective date and transition requirements in the May 2014 revenue standard (Accounting Standards Codification 606). The Company is currently assessing the adoption methodology and the impact the adoption of these ASUs will have on its
consolidated financial position, results of operations and related disclosures.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 2 - Liquidity and Management's Plans (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]
   
Total
   
0 to 3
months
   
3 to 6
months
   
6 to 12
months
 
Note due Redpath Equityholders
  $ 2,668     $ -     $ -     $ 2,668  
Severance obligations
    3,675       2,774       901       -  
Department of Justice ("DOJ") settlement
    750       -       85       665 *
Asuragen Deferred Purchase Price
    500       300       200       -  
Total obligations
  $ 7,593     $ 3,074     $ 1,186     $ 3,333  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 3 - Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Other Assets [Table Text Block]
   
March 31, 2016
   
December 31, 2015
 
Indemnification assets
  $ 1,375     $ 875  
Letters of credit
    344       360  
Other receivables
    960       1,048  
Prepaid expenses
    243       180  
Other
    102       106  
    $ 3,024     $ 2,569  
Schedule of Weighted Average Number of Shares [Table Text Block]
   
Three Months Ended
 
   
March 31,
 
   
2016
   
2015
 
Basic weighted average number 
of common shares
    17,762       15,037  
Potential dilutive effect of stock-based awards
    -       -  
Diluted weighted average number
of common shares
    17,762       15,037  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
March 31,
 
   
2016
   
2015
 
Options
    -       25  
Stock-settled stock appreciation rights (SARs)
    1,027       1,066  
Restricted stock and restricted stock units (RSUs)
    1,317       1,632  
Performance contingent SARs
    -       188  
      2,344       2,911  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 4 - Other Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
           
As of March 31, 2016
 
   
Life
   
Carrying
 
   
(Years)
   
Amount
 
Diagnostic assets:
 
 
 
 
 
 
 
 
Asuragen acquisition:
               
Thyroid
    9     $ 8,519  
Pancreas
    7       2,882  
Biobank
    4       1,575  
RedPath acquisition:
               
Pancreas test
    7       16,141  
Barrett's test
    9       18,351  
Total
          $ 47,468  
Diagnostic lab:
 
 
 
 
 
 
 
 
CLIA Lab
    2.3     $ 609  
                 
Accumulated Amortization
          $ (5,555 )
                 
Net Carrying Value
          $ 42,522  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
2016
   
2017
   
2018
   
2019
   
2020
 
$ 4,889     $ 6,097     $ 5,949     $ 5,703     $ 5,703  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 5 - Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Fair Value, by Balance Sheet Grouping [Table Text Block]
   
As of March 31, 2016
   
Fair Value Measurements
 
   
Carrying
   
Fair
   
As of March 31, 2016
 
   
Amount
   
Value
   
Level 1
   
Level 2
     
Level 3
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
                                         
Cash
  $ 3,564     $ 3,564     $ 3,564     $ -  
 
  $ -  
Money market funds
    776       776       776       -         -  
    $ 4,340     $ 4,340     $ 4,340     $ -       $ -  
Marketable securities:
                                         
U.S. Treasury securities
  $ 553     $ 553     $ 553     $ -       $ -  
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration:
                                         
Asuragen
  $ 4,628     $ 4,628     $ -     $ -       $ 4,628  
RedPath
    13,921       13,921       -       -         13,921  
    $ 18,549     $ 18,549     $ -     $ -       $ 18,549  
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 6 - Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Restructuring and Related Costs [Table Text Block]
   
Continuing
   
Discontinued
         
   
Operations
   
Operations
   
Total
 
                         
Balance as of December 31, 2015
  $ 2,011     $ 1,074     $ 3,085  
Accruals
    459       659       1,118  
Payments
    (140 )     (388 )     (528 )
Balance as of March 31, 2016
  $ 2,330     $ 1,345     $ 3,675  
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 7 - Accrued Expenses and Long-term Liabilities (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   
March 31, 2016
   
December 31, 2015
 
Facilities realignment accrual
  $ -     $ 43  
Self insurance accruals
    66       137  
Indemnification liability
    875       875  
Contingent consideration
    659       659  
Rent payable
    104       127  
DOJ settlement
    750       250  
Accrued professional fees
    1,084       775  
Taxes payable
    622       591  
Unclaimed property
    544       546  
All others
    1,951       1,958  
    $ 6,655     $ 5,961  
Schedule of Other Assets and Other Liabilities [Table Text Block]
   
March 31, 2016
   
December 31, 2015
 
Rent payable
  $ 27     $ 52  
Uncertain tax positions
    3,468       3,425  
DOJ settlement (indemnified by RedPath)
    1,000       2,500  
Other
    201       201  
    $ 4,696     $ 6,178  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 8 - Stock-based Compensation (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
   
Three Months Ending
 
   
March 31,
 
   
2016
   
2015
 
Risk-free interest rate
    -       0.97%  
Expected life (years)
    -       3.5  
Expected volatility
    -       52.03%  
Dividend yield
    -       -  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 9 - Income Taxes (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
Three Months Ended
 
   
March 31,
 
   
2016
   
2015
 
Provision (benefit) for income tax
  $ 9     $ (73 )
Effective income tax rate
    0.2 %     1.0 %
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 11 - Discontinued Operations (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Components of Loss from Discontinued Operations [Table Text Block]
   
Three Months Ending March 31,
 
   
2016
   
2015
 
Revenue, net
  $ 1,644     $ 36,463  
                 
(Loss) income from discontinued operations, before tax
    (735 )*     3,118  
Income tax expense
    45       1  
(Loss) income from discontinued operations, net of tax
  $ (780 )   $ 3,117  
Discontinued Operation, Schedule of Amounts Recognized in Balance Sheet [Table Text Block]
   
For the Three Months Ended
March 31, 2016
   
For the Year Ended
December 31, 2015
 
   
CSO
   
DCA/
TVG
   
Total
   
CSO
   
DCA/
TVG
   
Total
 
Accounts receivable, net
  735     -     735     3,296     -     3,296  
Unbilled receivable, net
    -       -       -       16       -       16  
Other
    795       -       795       2,062       -       2,062  
Current assets from discontinued operations
    1,530       -       1,530       5,374       -       5,374  
Property and equipment, net
    33       -       33       190       -       190  
Other
    -       150       150       -       150       150  
Long-term assets from discontinued operations
    33       150       183       190       150       340  
Total assets
  1,563     150     1,713     5,564     150     5,714  
                                                 
Accounts payable
  2,195     -     2,195     3,767     -     3,767  
Unearned contract revenue
    -       -       -       11       -       11  
Accrued salary and bonus
    2,219       -       2,219       3,036       -       3,036  
Other
    1,812       288       2,100       5,092       358       5,450  
Current liabilities from discontinued operations
    6,226       288       6,514       11,906       358       12,264  
Total liabilities
  6,226     $ 288     6,514     11,906     358     12,264  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 12 - Long-term Debt (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Debt [Table Text Block]
   
2016
 
2017
 
2018
Note
  $ 1,334       $ 5,335       $ 4,001    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 13 - Supplemental Cash Flow Information (Tables)
3 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
   
For The Three Months Ended March 31
 
   
2016
   
2015
 
Net cash (used in) provided by operating activities of discontinued operations
  $ (2,171 )   $ 6,073  
                 
Net cash provided by (used in) investing activities of discontinued operations
  $ -     $ -  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 2 - Liquidity and Management's Plans (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Dec. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2014
Net Income (Loss) Attributable to Parent   $ (4,786) $ (3,868)  
Net Cash Provided by (Used in) Operating Activities   (3,970) (5,617)  
Cash and Cash Equivalents, at Carrying Value $ 8,310 4,340 $ 17,004 $ 23,111
Accounts Receivable, Net 2,806 2,780    
Liabilities, Current 23,373 $ 19,746    
Proceeds from Sale of Productive Assets 26,800      
Repayments of Long-term Debt $ 21,600      
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 2 - Contractual Obligations Due in the Next 12 Months (Details)
Mar. 31, 2016
USD ($)
Notes Payable, Other Payables [Member]  
Contractual Obligations, Due $ 2,668
Contractual Obligations, Due in 0 to 3 Months
Contractual Obligations, Due in 3 to 6 Months
Contractual Obligations, Due in 6 to 12 Months $ 2,668
DOJ Settlement [Member]  
Contractual Obligations, Due $ 750
Contractual Obligations, Due in 0 to 3 Months
Contractual Obligations, Due in 3 to 6 Months $ 85
Contractual Obligations, Due in 6 to 12 Months 665 [1]
Employee Severance [Member]  
Contractual Obligations, Due 3,675
Contractual Obligations, Due in 0 to 3 Months 2,774
Contractual Obligations, Due in 3 to 6 Months $ 901
Contractual Obligations, Due in 6 to 12 Months
Interpace Diagnostics, LLC [Member]  
Contractual Obligations, Due $ 500
Contractual Obligations, Due in 0 to 3 Months 300
Contractual Obligations, Due in 3 to 6 Months $ 200
Contractual Obligations, Due in 6 to 12 Months
Contractual Obligations, Due $ 7,593
Contractual Obligations, Due in 0 to 3 Months 3,074
Contractual Obligations, Due in 3 to 6 Months 1,186
Contractual Obligations, Due in 6 to 12 Months $ 3,333
[1] Estimated liability based on our current revenue expectation.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 3 - Summary of Significant Accounting Policies (Details Textual)
$ in Millions
Mar. 31, 2016
USD ($)
Allowance for Doubtful Accounts Receivable $ 0.9
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 3 - Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Indemnification assets $ 1,375 $ 875
Letters of credit 344 360
Other receivables 960 1,048
Prepaid expenses 243 180
Other 102 106
$ 3,024 $ 2,569
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 3 - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) - shares
shares in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Basic weighted average number of common shares (in shares) 17,762 15,037
Potential dilutive effect of stock-based awards (in shares)
Diluted weighted average number of common shares (in shares) 17,762 15,037
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 3 - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) - shares
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Employee Stock Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 25
Stock Appreciation Rights (SARs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1,027 1,066
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1,317 1,632
Performance Shares [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 188
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 2,344 2,911
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 4 - Other Intangible Assets (Details Textual) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Amortization of Intangible Assets $ 970 $ 870
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 4 - Identifiable Intangible Assets Carrying Value (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
Diagnostic Test, Thyroid [Member] | Asuragen [Member]  
Finite-lived intangible asset, useful life 9 years
Finite-Lived Intangible Assets, Net $ 8,519
Diagnostic Test, Pancreas [Member] | Asuragen [Member]  
Finite-lived intangible asset, useful life 7 years
Finite-Lived Intangible Assets, Net $ 2,882
Diagnostic Test, Pancreas [Member] | RedPath [Member]  
Finite-lived intangible asset, useful life 7 years
Finite-Lived Intangible Assets, Net $ 16,141
Diagnostic Test, Biobank [Member] | Asuragen [Member]  
Finite-lived intangible asset, useful life 4 years
Finite-Lived Intangible Assets, Net $ 1,575
Diagnostic Test, Barrett's RedPath [Member] | RedPath [Member]  
Finite-lived intangible asset, useful life 9 years
Finite-Lived Intangible Assets, Net $ 18,351
CLIA Diagnostic Lab [Member]  
Finite-lived intangible asset, useful life 2 years 109 days
Finite-Lived Intangible Assets, Net $ 609
RedPath [Member]  
Finite-Lived Intangible Assets, Net 47,468
Finite-Lived Intangible Assets, Net 42,522
Finite-Lived Intangible Assets, Accumulated Amortization $ (5,555)
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 4 - Future Estimated Amortization Expense (Details)
$ in Thousands
Mar. 31, 2016
USD ($)
2016 $ 4,889
2017 6,097
2018 5,949
2019 5,703
2020 $ 5,703
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 5 - Fair Value Measurements (Details Textual) - Asuragen and Redpath [Member]
$ in Millions
3 Months Ended
Mar. 31, 2016
USD ($)
Business Combination, Contingent Cash Consideration, Deferred Payments $ 4.6
Business Combination, Contingent Cash Consideration, Revenue Based Payments $ 13.9
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 5 - Financial Instruments (Details)
$ in Thousands
Mar. 31, 2016
USD ($)
Cash [Member] | Reported Value Measurement [Member]  
Cash and cash equivalents, fair value disclosure $ 3,564
Cash [Member] | Estimate of Fair Value Measurement [Member]  
Cash and cash equivalents, fair value disclosure 3,564
Cash [Member] | Fair Value, Inputs, Level 1 [Member]  
Cash and cash equivalents, fair value disclosure $ 3,564
Cash [Member] | Fair Value, Inputs, Level 2 [Member]  
Cash and cash equivalents, fair value disclosure
Cash [Member] | Fair Value, Inputs, Level 3 [Member]  
Cash and cash equivalents, fair value disclosure
Money Market Funds [Member] | Reported Value Measurement [Member]  
Cash and cash equivalents, fair value disclosure $ 776
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]  
Cash and cash equivalents, fair value disclosure 776
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]  
Cash and cash equivalents, fair value disclosure $ 776
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]  
Cash and cash equivalents, fair value disclosure
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]  
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]  
Cash and cash equivalents, fair value disclosure $ 4,340
Reported Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]  
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]  
Cash and cash equivalents, fair value disclosure
Reported Value Measurement [Member] | US Treasury Securities [Member]  
Investments, fair value disclosure $ 553
Reported Value Measurement [Member] | Asuragen [Member]  
Contingent consideration, deferred payments 4,628
Reported Value Measurement [Member] | RedPath [Member]  
Contingent consideration, deferred payments 13,921
Reported Value Measurement [Member]  
Cash and cash equivalents, fair value disclosure 4,340
Investments, fair value disclosure 18,549
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member]  
Investments, fair value disclosure 553
Estimate of Fair Value Measurement [Member] | Asuragen [Member]  
Contingent consideration, deferred payments 4,628
Estimate of Fair Value Measurement [Member] | RedPath [Member]  
Contingent consideration, deferred payments 13,921
Estimate of Fair Value Measurement [Member]  
Cash and cash equivalents, fair value disclosure 4,340
Investments, fair value disclosure 18,549
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]  
Investments, fair value disclosure $ 553
Fair Value, Inputs, Level 1 [Member] | Asuragen [Member]  
Contingent consideration, deferred payments
Fair Value, Inputs, Level 1 [Member] | RedPath [Member]  
Contingent consideration, deferred payments
Fair Value, Inputs, Level 1 [Member]  
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]  
Investments, fair value disclosure
Fair Value, Inputs, Level 2 [Member] | Asuragen [Member]  
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member] | RedPath [Member]  
Contingent consideration, deferred payments
Fair Value, Inputs, Level 2 [Member]  
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]  
Investments, fair value disclosure
Fair Value, Inputs, Level 3 [Member] | Asuragen [Member]  
Contingent consideration, deferred payments $ 4,628
Fair Value, Inputs, Level 3 [Member] | RedPath [Member]  
Contingent consideration, deferred payments 13,921
Fair Value, Inputs, Level 3 [Member]  
Investments, fair value disclosure $ 18,549
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 6 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 16, 2015
Jun. 03, 2015
Oct. 31, 2014
May. 31, 2016
Mar. 31, 2016
Oct. 31, 2015
Mar. 31, 2016
Dec. 31, 2015
Former Owners of RedPath [Member]                
Business Combination, Indemnification Assets, Amount as of Acquisition Date     $ 2,500,000          
RedPath Integrated Pathology, Inc [Member]                
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares           500,000    
Business Combination, Indemnification Assets, Amount as of Acquisition Date         $ 1,500,000   $ 1,500,000  
Business Combination, Indemnification Assets, Amount as of Acquisition Date, Current         500,000   500,000  
Business Combination, Indemnification Assets, Amount as of Acquisition Date, Noncurrent         1,000,000   1,000,000  
Other Accrued Expenses [Member]                
Regulatory Liabilities         800,000   800,000  
Other Noncurrent Liabilities [Member]                
Regulatory Liabilities         1,000,000   1,000,000  
Subsequent Event [Member]                
Litigation Settlement, Amount       $ 250,000        
Continuing Operations [Member]                
Severance Costs             500,000  
Letters of Credit Outstanding, Amount         $ 500,000   $ 500,000  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 500,000   500,000   500,000      
Common Stock, Par or Stated Value Per Share     $ 0.01   $ 0.01   $ 0.01 $ 0.01
Adjustments to Additional Paid in Capital, Other $ (6,100,000)       $ (6,800,000)      
Stock Issued During Period, Value, Treasury Stock Reissued $ 6,100,000       6,800,000      
Litigation Settlement, Amount     $ 3,000,000          
Business Combination, Indemnification Assets, Amount as of Acquisition Date     $ 500,000          
Regulatory Liabilities         $ 1,800,000   $ 1,800,000  
Loss Contingency, Damages Sought, Value   $ 500,000            
Notes Issued   $ 1,500,000            
Severance Costs             $ 1,100,000 $ 3,700,000
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 6 - Severance Activity (Details) - Employee Severance [Member]
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
Continuing Operations [Member]  
Balance as of December 31, 2015 $ 2,011
Accruals 459
Payments (140)
Balance as of March 31, 2016 2,330
Discontinued Operations [Member]  
Balance as of December 31, 2015 1,074
Accruals 659
Payments (388)
Balance as of March 31, 2016 1,345
Balance as of December 31, 2015 3,085
Accruals 1,118
Payments (528)
Balance as of March 31, 2016 $ 3,675
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 7 - Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Facilities realignment accrual $ 43
Self insurance accruals $ 66 137
Indemnification liability 875 875
Contingent consideration 659 659
Rent payable 104 127
DOJ settlement 750 250
Accrued professional fees 1,084 775
Taxes payable 622 591
Unclaimed property 544 546
All others 1,951 1,958
$ 6,655 $ 5,961
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 7 - Oher Long-term Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Rent payable $ 27 $ 52
Uncertain tax positions 3,468 3,425
DOJ settlement (indemnified by RedPath) 1,000 2,500
Other Liabilities Noncurrent 201 201
$ 4,696 $ 6,178
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 8 - Stock-based Compensation (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 29, 2016
Feb. 29, 2016
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Stock Appreciation Rights (SARs) [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage         33.33%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period         5 years
RSU's and Restricted Stock [Member] | Director [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 33.33%        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period   1.3      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 0.25      
RSU's and Restricted Stock [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         3 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized         2,450,000
Allocated Share-based Compensation Expense     $ 0.1 $ 0.2  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 8 - Weighted Average Assumptions (Details)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Risk-free interest rate 0.97%
Expected life (years) 3 years 182 days
Expected volatility 52.03%
Dividend yield 0.00%
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 9 - Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Provision (benefit) for income tax $ 9 $ (73)
Effective income tax rate 0.20% 1.00%
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 10 - Segment Information (Details Textual)
12 Months Ended
Dec. 31, 2015
Number of Reportable Segments 1
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 11 - Discontinued Operations (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Discontinued Operations [Member]    
Severance Costs $ 659,000  
Severance Costs $ 1,100,000 $ 3,700,000
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 11 - Results Included in Loss From Discontinued Operations, Net of Tax (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue, net $ 1,644 $ 36,463
(Loss) income from discontinued operations, before tax (735) [1] 3,118
Income tax expense 45 1
(Loss) income from discontinued operations, net of tax $ (780) $ 3,117
[1] Approximately $659,000 of the balance relates to severance relating to terminated employees.
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 11 - Assets and Liabilities Classified as Discontinued Operations (Details) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Commercial Services [Member]    
Accounts receivable, net $ 735 $ 3,296
Unbilled receivable, net 16
Other $ 795 2,062
Current assets from discontinued operations 1,530 5,374
Property and equipment, net $ 33 $ 190
Other
Long-term assets from discontinued operations $ 33 $ 190
Total assets 1,563 5,564
Accounts payable $ 2,195 3,767
Unearned contract revenue 11
Accrued salary and bonus $ 2,219 3,036
Other, liabilities 1,812 5,092
Current liabilities from discontinued operations 6,226 11,906
Total liabilities $ 6,226 $ 11,906
Other Discontinued Operations [Member]    
Accounts receivable, net
Unbilled receivable, net
Other
Current assets from discontinued operations
Property and equipment, net
Other $ 150 $ 150
Long-term assets from discontinued operations 150 150
Total assets $ 150 $ 150
Accounts payable
Unearned contract revenue
Accrued salary and bonus
Other, liabilities $ 288 $ 358
Current liabilities from discontinued operations 288 358
Total liabilities 288 358
Accounts receivable, net $ 735 3,296
Unbilled receivable, net 16
Other $ 795 2,062
Current assets from discontinued operations 1,530 5,374
Property and equipment, net 33 190
Other 150 150
Long-term assets from discontinued operations 183 340
Total assets 1,713 5,714
Accounts payable $ 2,195 3,767
Unearned contract revenue 11
Accrued salary and bonus $ 2,219 3,036
Other, liabilities 2,100 5,450
Current liabilities from discontinued operations 6,514 12,264
Total liabilities $ 6,514 $ 12,264
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 12 - Long-term Debt (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Dec. 22, 2015
Jun. 16, 2015
Oct. 31, 2014
Mar. 31, 2016
Oct. 31, 2015
Mar. 31, 2016
Jun. 30, 2015
Mar. 31, 2015
RedPath Integrated Pathology, Inc [Member] | Notes Payable, Other Payables [Member]                
Debt Instrument, Face Amount     $ 11,000,000          
Business Combination, Consideration Transferred, Liabilities Incurred     $ 7,500,000          
Debt Instrument, Interest Rate, Stated Percentage     5.00%          
Interest Expense, Debt           $ 200,000   $ 200,000
RedPath Integrated Pathology, Inc [Member] | Loans Payable [Member]                
Debt Instrument, Face Amount     $ 20,000,000          
Debt Instrument, One Time Payment, Principal         $ 1,333,750      
Proceeds from Issuance of Debt     $ 19,600,000          
RedPath Integrated Pathology, Inc [Member]                
Business Combination, Consideration Transferred, Liabilities Incurred             $ 10,700,000  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares         500,000      
Business Combination, Indemnification Assets, Amount as of Acquisition Date       $ 1,500,000   1,500,000    
Business Combination, Indemnification Assets, Amount as of Acquisition Date, Current       500,000   500,000    
Business Combination, Indemnification Assets, Amount as of Acquisition Date, Noncurrent       1,000,000   1,000,000    
Notes Payable, Other Payables [Member]                
Long-term Debt       8,600,000   8,600,000    
Debt Instrument, Unamortized Discount       $ 2,100,000   2,100,000    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares   500,000 500,000 500,000        
Interest Expense, Debt           $ 203,000   $ 848,000
Business Combination, Indemnification Assets, Amount as of Acquisition Date     $ 500,000          
Payments for Other Fees $ 1,600,000              
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 12 - Long-Term Debt Future Principal Payments (Details)
$ in Thousands
Mar. 31, 2016
USD ($)
2016 $ 1,334
2017 5,335
2018 $ 4,001
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.4.0.3
Note 13 - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Net cash (used in) provided by operating activities of discontinued operations $ (2,171) $ 6,073
Net cash provided by (used in) investing activities of discontinued operations
EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 107 233 1 true 37 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.interpacediagnostics.com/20160331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.interpacediagnostics.com/20160331/role/statement-condensed-consolidated-balance-sheets-unaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.interpacediagnostics.com/20160331/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.interpacediagnostics.com/20160331/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://www.interpacediagnostics.com/20160331/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited-parentheticals Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.interpacediagnostics.com/20160331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-1-basis-of-presentation Note 1 - Basis of Presentation Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Liquidity and Management's Plans Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-2-liquidity-and-managements-plans Note 2 - Liquidity and Management's Plans Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-3-summary-of-significant-accounting-policies Note 3 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Other Intangible Assets Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-4-other-intangible-assets Note 4 - Other Intangible Assets Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-5-fair-value-measurements- Note 5 - Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-7-accrued-expenses-and-longterm-liabilities Note 7 - Accrued Expenses and Long-term Liabilities Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Stock-based Compensation Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-8-stockbased-compensation- Note 8 - Stock-based Compensation Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Income Taxes Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-9-income-taxes Note 9 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Segment Information Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-10-segment-information Note 10 - Segment Information Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Discontinued Operations Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-11-discontinued-operations Note 11 - Discontinued Operations Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Long-term Debt Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-12-longterm-debt Note 12 - Long-term Debt Notes 18 false false R19.htm 018 - Document - Note 13 - Supplemental Cash Flow Information Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-13-supplemental-cash-flow-information- Note 13 - Supplemental Cash Flow Information Uncategorized 19 false false R20.htm 019 - Disclosure - Note 14 - Recent Accounting Pronouncements Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-14-recent-accounting-pronouncements Note 14 - Recent Accounting Pronouncements Uncategorized 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.interpacediagnostics.com/20160331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 2 - Liquidity and Management's Plans (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-2-liquidity-and-managements-plans-tables Note 2 - Liquidity and Management's Plans (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 4 - Other Intangible Assets (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-4-other-intangible-assets-tables Note 4 - Other Intangible Assets (Tables) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 6 - Commitments and Contingencies (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-6-commitments-and-contingencies-tables Note 6 - Commitments and Contingencies (Tables) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 7 - Accrued Expenses and Long-term Liabilities (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-7-accrued-expenses-and-longterm-liabilities-tables Note 7 - Accrued Expenses and Long-term Liabilities (Tables) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 8 - Stock-based Compensation (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-8-stockbased-compensation-tables Note 8 - Stock-based Compensation (Tables) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 9 - Income Taxes (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-9-income-taxes-tables Note 9 - Income Taxes (Tables) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 11 - Discontinued Operations (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-11-discontinued-operations-tables Note 11 - Discontinued Operations (Tables) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 12 - Long-term Debt (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-12-longterm-debt-tables Note 12 - Long-term Debt (Tables) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 13 - Supplemental Cash Flow Information (Tables) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-13-supplemental-cash-flow-information-tables Note 13 - Supplemental Cash Flow Information (Tables) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 2 - Liquidity and Management's Plans (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-2-liquidity-and-managements-plans-details-textual Note 2 - Liquidity and Management's Plans (Details Textual) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 2 - Contractual Obligations Due in the Next 12 Months (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-2-contractual-obligations-due-in-the-next-12-months-details Note 2 - Contractual Obligations Due in the Next 12 Months (Details) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 3 - Other Current Assets (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-3-other-current-assets-details Note 3 - Other Current Assets (Details) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 3 - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-3-reconciliation-of-the-number-of-shares-used-in-basic-and-diluted-earnings-per-share-details Note 3 - Reconciliation of the Number of Shares Used in Basic and Diluted Earnings Per Share (Details) Uncategorized 37 false false R38.htm 037 - Disclosure - Note 3 - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-3-stock-awards-excluded-from-the-computation-of-the-effect-of-dilutive-securities-details Note 3 - Stock Awards Excluded from the Computation of the Effect of Dilutive Securities (Details) Uncategorized 38 false false R39.htm 038 - Disclosure - Note 4 - Other Intangible Assets (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-4-other-intangible-assets-details-textual Note 4 - Other Intangible Assets (Details Textual) Uncategorized 39 false false R40.htm 039 - Disclosure - Note 4 - Identifiable Intangible Assets Carrying Value (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-4-identifiable-intangible-assets-carrying-value-details Note 4 - Identifiable Intangible Assets Carrying Value (Details) Uncategorized 40 false false R41.htm 040 - Disclosure - Note 4 - Future Estimated Amortization Expense (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-4-future-estimated-amortization-expense-details Note 4 - Future Estimated Amortization Expense (Details) Uncategorized 41 false false R42.htm 041 - Disclosure - Note 5 - Fair Value Measurements (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-5-fair-value-measurements-details-textual Note 5 - Fair Value Measurements (Details Textual) Uncategorized 42 false false R43.htm 042 - Disclosure - Note 5 - Financial Instruments (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-5-financial-instruments-details Note 5 - Financial Instruments (Details) Uncategorized 43 false false R44.htm 043 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Uncategorized 44 false false R45.htm 044 - Disclosure - Note 6 - Severance Activity (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-6-severance-activity-details Note 6 - Severance Activity (Details) Uncategorized 45 false false R46.htm 045 - Disclosure - Note 7 - Accrued Expenses (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-7-accrued-expenses-details Note 7 - Accrued Expenses (Details) Uncategorized 46 false false R47.htm 046 - Disclosure - Note 7 - Oher Long-term Liabilities (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-7-oher-longterm-liabilities-details Note 7 - Oher Long-term Liabilities (Details) Uncategorized 47 false false R48.htm 047 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-8-stockbased-compensation-details-textual Note 8 - Stock-based Compensation (Details Textual) Uncategorized 48 false false R49.htm 048 - Disclosure - Note 8 - Weighted Average Assumptions (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-8-weighted-average-assumptions-details Note 8 - Weighted Average Assumptions (Details) Uncategorized 49 false false R50.htm 049 - Disclosure - Note 9 - Income Taxes (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-9-income-taxes-details Note 9 - Income Taxes (Details) Uncategorized 50 false false R51.htm 050 - Disclosure - Note 10 - Segment Information (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-10-segment-information-details-textual Note 10 - Segment Information (Details Textual) Uncategorized 51 false false R52.htm 051 - Disclosure - Note 11 - Discontinued Operations (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-11-discontinued-operations-details-textual Note 11 - Discontinued Operations (Details Textual) Uncategorized 52 false false R53.htm 052 - Disclosure - Note 11 - Results Included in Loss From Discontinued Operations, Net of Tax (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-11-results-included-in-loss-from-discontinued-operations-net-of-tax-details Note 11 - Results Included in Loss From Discontinued Operations, Net of Tax (Details) Uncategorized 53 false false R54.htm 053 - Disclosure - Note 11 - Assets and Liabilities Classified as Discontinued Operations (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-11-assets-and-liabilities-classified-as-discontinued-operations-details Note 11 - Assets and Liabilities Classified as Discontinued Operations (Details) Uncategorized 54 false false R55.htm 054 - Disclosure - Note 12 - Long-term Debt (Details Textual) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-12-longterm-debt-details-textual Note 12 - Long-term Debt (Details Textual) Uncategorized 55 false false R56.htm 055 - Disclosure - Note 12 - Long-Term Debt Future Principal Payments (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-12-longterm-debt-future-principal-payments-details Note 12 - Long-Term Debt Future Principal Payments (Details) Uncategorized 56 false false R57.htm 056 - Disclosure - Note 13 - Supplemental Cash Flow Information (Details) Sheet http://www.interpacediagnostics.com/20160331/role/statement-note-13-supplemental-cash-flow-information-details Note 13 - Supplemental Cash Flow Information (Details) Uncategorized 57 false false All Reports Book All Reports idxg-20160331.xml idxg-20160331.xsd idxg-20160331_cal.xml idxg-20160331_def.xml idxg-20160331_lab.xml idxg-20160331_pre.xml true true ZIP 75 0001437749-16-031581-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-16-031581-xbrl.zip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